Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
25 "Jong-Mu Sun"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Clinical Relevance of Starting Alectinib at a Reduced Dose in Patients with ALK-Positive Non-Small Cell Lung Cancer
Junkyu Kim, Min-Ji Kim, Jinyong Kim, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun
Received December 14, 2024  Accepted April 22, 2025  Published online April 24, 2025  
DOI: https://doi.org/10.4143/crt.2024.1209    [Accepted]
AbstractAbstract PDF
Purpose
Alectinib has been approved for Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) at 300mg twice daily in Japan, lower than global standard of 600mg twice daily. This study evaluated the clinical relevance of the reduced dose by comparing outcomes between the two doses.
Materials and Methods
This study included patients with advanced ALK-positive NSCLC who received alectinib at Samsung Medical Center, Korea. The progression-free survival (PFS), overall survival, cumulative incidence of central nervous system (CNS) progression, and safety profiles were retrospectively reviewed and compared.
Results
Among 306 patients, 32 and 274 received alectinib at either 300 or 600 mg twice daily, respectively. The 300 mg group showed a slight but not significant advantage in PFS (HR 0.82, 95% CI, 0.44-1.51; p=0.51) and overall survival (HR 0.51, 95% CI, 0.20-1.21; p=0.13). Superior outcome with 300mg was remarkable in patients with lower body weight (≤60 kg), but diminished in patients with higher body weights. Patients with baseline brain metastasis in the 300mg group exhibited a slight increase in incidence of CNS failure (HR 1.76, 95% CI, 0.53-5.8; p=0.36). Although the safety profiles were mostly mild, adverse events were more frequent in the 600mg group, 50% of which requiring dose reduction.
Conclusion
Alectinib at 300 mg twice daily seems an acceptable dose in East Asians with ALK-positive NSCLC. Notably, our data favor 300 mg twice daily in patients with lower body weight and no baseline brain metastasis, considering the more tolerable safety profiles and the potential to reduce medical costs.
  • 475 View
  • 44 Download
Close layer
Gastrointestinal cancer
Salvage Radiotherapy for Loco-regional Recurrence of Esophageal Cancer Following Surgery
Won Kyung Cho, Jae Myoung Noh, Dongryul Oh, Yong Chan Ahn, Jong-Mu Sun, Hong Kwan Kim, Young Mog Shim
Cancer Res Treat. 2025;57(1):165-173.   Published online July 26, 2024
DOI: https://doi.org/10.4143/crt.2024.191
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
There is few evidence regarding the optimal salvage treatment options for loco-reginal recurrence of esophageal cancer. This study aimed to evaluate the clinical outcomes of salvage radiotherapy (RT) in patients with loco-regional recurrence (LRR) after surgery for esophageal cancer.
Materials and Methods
We retrospectively reviewed 147 esophageal cancer patients who received salvage RT for loco-regional recurrence between 1996 and December 2019. A total dose of 60 Gy in 20 fractions was used for RT alone and 60-70 Gy in 30-35 fractions for concurrent chemoradiotherapy (CCRT).
Results
The patients’ median age was 65 years (range, 41 to 86 years). The median disease-free interval was 13.5 months (1.0 to 97.4 months). After a median 18.8 months follow-up, the 2-year overall survival (OS) and progression-free survival (PFS) rates were 38.1% and 25.9%, respectively. The median OS and PFS were 18.8 and 8.4 months, respectively. The CCRT could not improve OS compared to RT (p=0.336), but there was a trend of better PFS in the CCRT group. Regarding toxicities, the rate of grade 3 or higher toxicity was 10.9% occurring in 16 patients, and it was higher in patients who received CCRT than in the RT alone group (19.6% vs. 6.3%, p=0.023).
Conclusion
Salvage RT alone as well as CCRT could be effective in patients with locoregionally recurrent esophageal cancer.

Citations

Citations to this article as recorded by  
  • Salvage Chemoradiotherapy for Loco-Regional Recurrence of Esophageal Squamous Cell Carcinoma After Esophagectomy
    Atsuto Katano, Tomoki Kiritoshi, Subaru Sawayanagi, Hideomi Yamashita
    Journal of Clinical Medicine.2025; 14(5): 1540.     CrossRef
  • 1,498 View
  • 90 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Lung and Thoracic cancer
Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non–Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial
Junghoon Shin, Sehhoon Park, Kyung Hwan Kim, Eui-Cheol Shin, Hyun Ae Jung, Jong Ho Cho, Jong-Mu Sun, Se-Hoon Lee, Yong Soo Choi, Jin Seok Ahn, Jhingook Kim, Keunchil Park, Young Mog Shim, Hong Kwan Kim, Jae Myoung Noh, Yong Chan Ahn, Hongryull Pyo, Myung-Ju Ahn
Cancer Res Treat. 2024;56(4):1084-1095.   Published online April 30, 2024
DOI: https://doi.org/10.4143/crt.2024.084
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Optimal treatment for stage IIIA/N2 non–small cell lung cancer (NSCLC) is controversial. We aimed to assess the efficacy and safety of adjuvant pembrolizumab for stage IIIA/N2 NSCLC completely resected after neoadjuvant concurrent chemoradiation therapy (CCRT).
Materials and Methods
In this open-label, single-center, single-arm phase 2 trial, patients with stage IIIA/N2 NSCLC received adjuvant pembrolizumab for up to 2 years after complete resection following neoadjuvant CCRT. The primary endpoint was disease-free survival (DFS). Secondary endpoints included overall survival (OS) and safety. As an exploratory biomarker analysis, we evaluated the proliferative response of blood CD39+PD-1+CD8+ T cells using fold changes in the percentage of proliferating Ki-67+ cells from days 1 to 7 of cycle 1 (Ki-67D7/D1).
Results
Between October 2017 and October 2018, 37 patients were enrolled. Twelve (32%) and three (8%) patients harbored EGFR and ALK alterations, respectively. Of 34 patients with programmed cell death ligand 1 assessment, 21 (62%), nine (26%), and four (12%) had a tumor proportion score of < 1%, 1%-50%, and ≥ 50%, respectively. The median follow-up was 71 months. The median DFS was 22.4 months in the overall population, with a 5-year DFS rate of 29%. The OS rate was 86% at 2 years and 76% at 5 years. Patients with tumor recurrence within 6 months had a significantly lower Ki-67D7/D1 among CD39+PD-1+CD8+ T cells than those without (p=0.036). No new safety signals were identified.
Conclusion
Adjuvant pembrolizumab may offer durable disease control in a subset of stage IIIA/N2 NSCLC patients after neoadjuvant CCRT and surgery.

Citations

Citations to this article as recorded by  
  • Adjuvant immunotherapy improves survival in completely resected stage IB–III NSCLC: a systematic review and meta-analysis
    Hong Huang, Pengchen Bao, Hongyu Jin, Wenyang Li, Hui Shen, Zhen Qin, Ying Pan, Xinming Su, Delei Kong
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • 3,155 View
  • 156 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Gastrointestinal cancer
Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study
Sehhoon Park, Yurimi Lee, Jiyun Lee, Yang Won Min, Hong Kwan Kim, Joon Young Choi, Hyun Ae Jung, Yong Soo Choi, Yoon-La Choi, Young Mog Shim, Jong-Mu Sun
Cancer Res Treat. 2024;56(2):567-579.   Published online October 16, 2023
DOI: https://doi.org/10.4143/crt.2023.897
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors have shown efficacy in metastatic esophageal squamous cell carcinoma (ESCC) therapy. However, data is still limited regarding neoadjuvant immunotherapy for operable ESCC.
Materials and Methods
Patients with clinical stage T2 or T3 and N0 ESCC received three cycles of nivolumab therapy every two weeks before surgical resection. The primary endpoint is major pathologic responses (MPR) rate (≤ 10% of residual viable tumor [RVT]).
Results
Total 20 patients completed the planned nivolumab therapy. Among them, 17 patients underwent surgery as protocol, showing MPR in two patients (MPR rate, 11.8%), including one pathologic complete response, on conventional pathologic response evaluation. Pathologic response was re-evaluated using the immune-related pathologic response criteria based on immune-related RVT (irRVT). Three patients were classified as immunologic major pathologic response (iMPR; ≤ 10% irRVT, iMPR rate: 17.6%), five as pathologic partial response (> 10% and < 90% irRVT), and nine as pathologic nonresponse (≥ 90% irRVT). The combined positive score (CPS) for PD-L1 in the baseline samples was predictable for iMPR, with the probability as 37.5% in CPS ≥ 10 (3/8) and 0% in CPS < 10 (0/9).
Conclusion
Although the efficacy of neoadjuvant nivolumab therapy was modest in unselected ESCC patients, further researches on neoadjuvant immunotherapy are necessary in patients with PD-L1 expressed ESCC.
  • 4,189 View
  • 177 Download
  • 1 Web of Science
Close layer
Lung and Thoracic cancer
First-Line Alectinib vs. Brigatinib in Advanced Non–Small Cell Lung Cancer with ALK Rearrangement: Real-World Data
Youngkyung Jeon, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
Cancer Res Treat. 2024;56(1):61-69.   Published online July 14, 2023
DOI: https://doi.org/10.4143/crt.2023.461
AbstractAbstract PDFPubReaderePub
Purpose
Alectinib and brigatinib are second-generation anaplastic lymphoma receptor tyrosine kinases (ALKs) that are widely used as first-line therapy for treating ALK-positive advanced non–small cell lung cancer (NSCLC). Given the lack of a head-to-head comparison of these drugs as first-line therapies, this retrospective observational study aimed to compare the real-world efficacy and safety of alectinib and brigatinib.
Materials and Methods
Patients who received alectinib or brigatinib as the first-line treatment for ALK-positive advanced NSCLC were evaluated for clinical outcomes of objective response rate (ORR), intracranial ORR, time to next treatment (TTNT), progression-free survival (PFS), overall survival (OS), and safety profiles.
Results
Of 208 patients who received either alectinib or brigatinib as a first-line treatment, 176 received alectinib and 32 received brigatinib. At the data cutoff point, the median follow-up duration was 16.5 months (95% confidence interval [CI], 14.7 to 18.3) in the brigatinib group and 27.5 months (95% CI, 24.6 to 30.4) in the alectinib group. The ORR was 92.5% with alectinib and 93.8% for brigatinib. The intracranial ORR rates were 92.7% (38/41) and 100% (10/10), respectively. The rate of PFS at 12 months was comparable between the alectinib group and the brigatinib groups (84.4% vs. 84.1%, p=0.64), and the median TTNT, PFS, and OS were not reached in either group. Treatment-related adverse events were usually mild, and treatment discontinuation due to adverse events was rare (alectinib 4.5% vs. brigatinib 6.25%).
Conclusion
Alectinib and brigatinib had similar clinical benefits when used as the first-line treatment of NSCLC patients with ALK rearrangement in the real world.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials
    D. Ross Camidge, Shunichi Sugawara, Masashi Kondo, Hye Ryun Kim, Myung-Ju Ahn, James C.H. Yang, Ji-Youn Han, Maximilian J. Hochmair, Ki Hyeong Lee, Angelo Delmonte, Kentarou Kudou, Takayuki Asato, Bradley Hupf, Florin Vranceanu, Robert J. Fram, Yuichiro O
    Lung Cancer.2025; 201: 108424.     CrossRef
  • Effectiveness of First-Line Treatment with Anaplastic Lymphoma Kinase and ROS1 Protoncogene Inhibitors in Non-Small Cell Lung Cancer Patients—Real-World Evidence of Two Polish Cancer Centers
    Michał Gil, Kinga Winiarczyk, Paweł Krawczyk, Kamila Wojas-Krawczyk, Aleksandra Łomża-Łaba, Adrian Obara, Łukasz Gajek, Katarzyna Reszka, Andrzej Tysarowski, Jarosław Buczkowski, Izabela Chmielewska, Tomasz Jankowski, Magdalena Szuba-Gil, Maciej Strzemski
    Cancers.2025; 17(7): 1253.     CrossRef
  • Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications
    Nyein Wint Yee Theik, Suset Almuinas De Armas, Daniel Rosas, Amy Kiamos, Nyein Nyein Thaw Dar, Ahmed Shoreibah, Atif Hussein, Luis E. Raez
    International Journal of Molecular Sciences.2025; 26(8): 3802.     CrossRef
  • Bridging the Gap between Trial Adverse Events and Real-World Data
    Sang Hyuk Kim, Hyun Lee, Dong Won Park
    Cancer Research and Treatment.2024; 56(3): 972.     CrossRef
  • Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK+ non‐small cell lung cancer using South Korean claims data (K‐AREAL)
    Jeong Eun Lee, Jin Hyun Nam, Sun Hong Kwon, Bo Kyung Kim, Seung Min Ha
    Cancer Medicine.2024;[Epub]     CrossRef
  • Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System
    Qiran Wei, Yifang Liang, Jiahui Mao, Xin Guan
    Cancer Medicine.2024;[Epub]     CrossRef
  • 6,053 View
  • 609 Download
  • 7 Web of Science
  • 6 Crossref
Close layer
Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
Youngkyung Jeon, Hyun Ae Jung, Sehhoon Park, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Se-Hoon Lee
Cancer Res Treat. 2023;55(4):1144-1151.   Published online May 22, 2023
DOI: https://doi.org/10.4143/crt.2023.403
AbstractAbstract PDFPubReaderePub
Purpose
Rearranged during transfection (RET) gene rearrangement is a well-known driver event in non–small cell lung cancer (NSCLC). Pralsetinib is a selective inhibitor of RET kinase and has shown efficacy in oncogenic RET-altered tumors. This study evaluated the efficacy and safety of expanded access program (EAP) use of pralsetinib in pretreated, advanced NSCLC patients with RET rearrangement.
Materials and Methods
Patients who received pralsetinib as part of the EAP at Samsung Medical Center were evaluated through a retrospective chart review. The primary endpoint was overall response rate (ORR) per the Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1 guidelines. Secondary endpoints were duration of response, progression-free survival (PFS), overall survival (OS), and safety profiles.
Results
Between April 2020 and September 2021, 23 of 27 patients were enrolled in the EAP study. Two patients who were not analyzed due to brain metastasis and two patients whose expected survival was within 1 month were excluded from the analysis. After a median follow-up period of 15.6 months (95% confidence interval [CI], 10.0 to 21.2), ORR was 56.5%, the median PFS was 12.1 months (95% CI, 3.3 to 20.9), and the 12-month OS rate was 69.6%. The most frequent treatment-related adverse events (TRAEs) were edema (43.5%) and pneumonitis (39.1%). A total of 8.7% of patients experienced extra-pulmonary tuberculosis. TRAEs with a common grade of three or worse were neutropenia (43.5%) and anemia (34.8%). Dose reduction was required in nine patients (39.1%).
Conclusion
Pralsetinib presents a clinical benefit when used in patients with RET-rearranged NSCLC, consistent with a pivotal study.

Citations

Citations to this article as recorded by  
  • Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC
    Francesca Lucibello, Valérie Gounant, Mihaela Aldea, Michaël Duruisseaux, Maurice Perol, Christos Chouaid, Jaafar Bennouna, Vincent Fallet, Aldo Renault, Florian Guisier, Etienne Giroux-Leprieur, Marie Wislez, Anne-Claire Toffart, Julien Mazieres, Clémenc
    JTO Clinical and Research Reports.2025; 6(1): 100743.     CrossRef
  • Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib
    Giuseppe Lo Russo, Paolo Bironzo, Chiara Bennati, Laura Bonanno, Annamaria Catino, Giulio Metro, Iacopo Petrini, Marco Russano, Antonio Passaro
    Critical Reviews in Oncology/Hematology.2024; 194: 104243.     CrossRef
  • RET Fusion Testing in Patients With NSCLC: The RETING Study
    Esther Conde, Susana Hernandez, Jose Luis Rodriguez Carrillo, Rebeca Martinez, Marta Alonso, Daniel Curto, Beatriz Jimenez, Alejandra Caminoa, Amparo Benito, Pilar Garrido, Sergi Clave, Edurne Arriola, Isabel Esteban-Rodriguez, Javier De Castro, Irene San
    JTO Clinical and Research Reports.2024; 5(4): 100653.     CrossRef
  • Efficacy and safety of pralsetinib in patients with RET fusion positive non–small cell lung cancer: An observational real world study
    Dehua Liao, Minghui Long, Jiwen Zhang, Xingyu Wei, Fei Li, Ting Yan, Desong Yang
    Lung Cancer.2024; 196: 107936.     CrossRef
  • 3,711 View
  • 218 Download
  • 5 Web of Science
  • 4 Crossref
Close layer
The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
Hyun Ae Jung, Sehhoon Park, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun
Cancer Res Treat. 2023;55(2):479-487.   Published online December 27, 2022
DOI: https://doi.org/10.4143/crt.2022.1344
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Brain metastasis is common in patients with epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer (NSCLC) at initial presentation. A previous study showed that brain radiotherapy (RT) before first-generation (first-G) EGFR–tyrosine kinase inhibitor (TKI) therapy is associated with longer overall survival than TKI therapy alone. However, there is no data regarding the role of additional brain RT before afatinib therapy.
Materials and Methods
Between October 2014 and June 2019, EGFR-mutant NSCLC patients with brain metastases who started first-G EGFR-TKIs (gefitinib or erlotinib) or afatinib as first-line therapy were retrospectively analyzed. This study compared overall survival and intracranial progression-free survival (PFS) between patients who received EGFR-TKIs alone and EGFR-TKIs with brain RT and either a first-G EGFR-TKI or afatinib, respectively.
Results
The median follow-up duration was 29.6 months (range, 1.5 to 116.9 months). In the first-G EGFR-TKI group (n=155), 94 patients (60.6%) received the first-G EGFR-TKI alone and 61 patients (39.4%) received brain RT prior to their first-G EGFR-TKI. In the afatinib group (n=204), 126 patients (61.8%) received afatinib alone and 78 patients (38.2%) received brain RT prior to afatinib. There was no difference in overall survival rates between the groups with RT (35.6 months: 95% confidence interval [CI], 27.9 to 43.3) and without RT (31.4 months: 95% CI, 23.9 to 38.9) in the afatinib group (p=0.58), but there was a significant difference in overall survival in the first-G EGFR-TKI group in a manner favoring additional brain RT (41.1 months: 95% CI, 30.5 to 51.7 vs. 25.8 months: 95% CI, 20.1 to 31.5; p=0.02). Meanwhile, median intracranial PFS was not different between patients who received EGFR-TKI therapy alone vs. EGFR-TKI therapy with brain RT in both the first-G EGFR-TKI (p=0.39) and afatinib (p=0.24) groups.
Conclusion
Afatinib therapy alone showed comparable survival outcomes to those of afatinib with brain RT. The current study suggests that brain RT could be an optional, not mandatory, treatment modality when afatinib therapy is considered in patients with EGFR-mutant NSCLC.

Citations

Citations to this article as recorded by  
  • Integrated single cell and bulk RNA sequencing analyses reveal the impact of tryptophan metabolism on prognosis and immunotherapy in colon cancer
    Yanyan Hu, Ximo Xu, Hao Zhong, Chengshen Ding, Sen zhang, Wei Qin, Enkui Zhang, Duohuo Shu, Mengqin Yu, Naijipu Abuduaini, Xiao Yang, Bo Feng, Jianwen Li
    Scientific Reports.2025;[Epub]     CrossRef
  • Radiation Recall Pneumonitis: The Open Challenge in Differential Diagnosis of Pneumonia Induced by Oncological Treatments
    Francesca Grassi, Vincenza Granata, Roberta Fusco, Federica De Muzio, Carmen Cutolo, Michela Gabelloni, Alessandra Borgheresi, Ginevra Danti, Carmine Picone, Andrea Giovagnoni, Vittorio Miele, Nicoletta Gandolfo, Antonio Barile, Valerio Nardone, Roberta G
    Journal of Clinical Medicine.2023; 12(4): 1442.     CrossRef
  • Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study
    H.A. Jung, S. Park, S.-H. Lee, J.S. Ahn, M.-J. Ahn, J.-M. Sun
    ESMO Open.2023; 8(6): 102068.     CrossRef
  • Recent advances progress of targeted drugs combined with radiotherapy for advanced non-small cell lung cancer: a review
    Jiamin Xu, Zhongming Wang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • 4,605 View
  • 157 Download
  • 5 Web of Science
  • 4 Crossref
Close layer
EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis
Hongsik Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
Cancer Res Treat. 2023;55(2):498-505.   Published online October 4, 2022
DOI: https://doi.org/10.4143/crt.2022.388
AbstractAbstract PDFPubReaderePub
Purpose
The impact of epidermal growth factor receptor (EGFR) mutation in locally advanced non–small cell lung cancer (NSCLC) remains controversial. This study was conducted to investigate the clinical outcomes and recurrence patterns after definitive chemoradiotherapy (CRT) in patients with unresectable stage III non-squamous-cell lung cancer according to EGFR mutation status.
Materials and Methods
We retrospectively reviewed 604 patients with pathologically confirmed stage III NSCLC who were treated with definitive CRT and were examined for EGFR mutation at Samsung Medical Center, Korea, from January 2013 to December 2018. Among them, we identified 236 patients with stage III non-squamous-cell lung cancer who were treated with definitive CRT and were examined for EGFR mutation status. We analyzed the frequency of EGFR mutation, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and recurrence pattern.
Results
Among 236 patients, EGFR mutation was detected in 71 patients (30.1%) and the median follow-up duration was 41.7 months. There were no significant differences in PFS (9.9 vs. 10.9 months, p=0.236), and ORR to CRT (93.0% vs. 90.3%, p=0.623) according to EGFR mutation status. However, the EGFR mutant group showed significantly higher recurrence (88.7% vs. 75.2%, p=0.022), distant metastasis (76.1% vs. 61.2%, p=0.036) rates, especially brain (38.0% vs. 12.7%, p < 0.001), and better median OS (59.2 vs. 41.3 months, p=0.037) compared with patients without EGFR mutation.
Conclusion
Patients with EGFR mutation–positive unresectable stage III non-squamous lung cancer exhibited higher recurrence and distant metastasis rates, especially brain metastasis.

Citations

Citations to this article as recorded by  
  • TFAP2A facilitates the metastasis and radioresistance of esophageal cancer by promoting EGFR transcription
    Jinjin Yuan, Junqi Liu, Ruitai Fai, Zongwen Liu
    Naunyn-Schmiedeberg's Archives of Pharmacology.2025;[Epub]     CrossRef
  • Cost-Effectiveness of Adjuvant Osimertinib With and Without Chemotherapy for Surgically Resected NSCLC
    Angelos Vasilopoulos, Alexander Pohlman, Ayham Odeh, K. Robert Shen, Julia M. Coughlin, Zaid M. Abdelsattar
    JTO Clinical and Research Reports.2025; 6(6): 100833.     CrossRef
  • Prognostic Factors in Postoperative Brain Metastases Derive From Non-small Cell Lung Cancer: A Retrospective Analysis
    Haibin Chen, Liang Sun, Zhi Yang, Yuanyuan Qu, Nanyang Tong, Caixing Sun, Liang Xia
    Clinical Medicine Insights: Oncology.2024;[Epub]     CrossRef
  • Brain metastasis screening in the molecular age
    Joanna K Tabor, Amanda Onoichenco, Vinayak Narayan, A Gabriella Wernicke, Randy S D’Amico, Morana Vojnic
    Neuro-Oncology Advances.2023;[Epub]     CrossRef
  • 5,501 View
  • 247 Download
  • 6 Web of Science
  • 4 Crossref
Close layer
Long-term Survival in Non–Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment
Hongsik Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2022;54(1):150-156.   Published online May 6, 2021
DOI: https://doi.org/10.4143/crt.2021.306
AbstractAbstract PDFPubReaderePub
Purpose
Metachronous brain-only oligorecurrence in patients with non–small cell lung cancer (NSCLC) is a rare event with favorable prognosis, but the clinical outcome has not been fully determined. We retrospectively analyzed clinical outcomes and prognostic factors in metachronous brain-only oligorecurrence in patients with NSCLC who underwent definitive treatment.
Materials and Methods
We reviewed 4,437 NSCLC patients without oncogenic driver mutations who underwent definitive treatment between 2008 and 2018. Among them, we identified 327 patients who developed 1 to 5 brain metastases with or without systemic metastasis. Of the 327 patients, 71 had metachronous brain-only oligorecurrence without extracranial progression and were treated with local therapy to the brain. Overall survival (OS), progression-free survival (PFS), and prognostic factors affecting OS were analyzed.
Results
The median OS was 38.9 months (95% confidence interval [CI], 21.8 to 56.1 months) in 71 patients. The 2-year OS rate was 67.8% and the 5-year OS rate was 33.1%. The median PFS was 25.5 months (95% CI, 12.2 to 14.4 months). The longest surviving patient had a survival period of 115 months. Through multivariate analysis, Eastern Cooperative Oncology Group ≥ 1 (hazard ratio, 5.33; p=0.005) was associated with poor survival. There was no significant difference in OS between patients with local therapy and those with local plus systemic therapy (18.5 months vs. 34.7 months, p=0.815).
Conclusion
Metachronous brain-only oligorecurrence NSCLC patients who underwent definitive treatment experienced long-term survival with local therapy, highlighting the unique patient population. The role of systemic chemotherapy in this patient population requires further investigation.

Citations

Citations to this article as recorded by  
  • Surgery for Stage IV Disease—Is It Prime Time Yet?
    Marianna V. Papageorge, Mara B. Antonoff
    Surgical Oncology Clinics of North America.2025;[Epub]     CrossRef
  • Analysis of prognostic factors and risk prediction in brain metastases: a SEER population-based study
    Qiang Ji, Zixuan Yang, Xun Kang, Lili Zhou, Feng Chen, Wenbin Li
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • ‘Perspectives of pulmonologists and thoracic surgeons on Oligometastatic disease: curability, treatment approaches, and disease trajectory’
    Damla Azaklı, Inanc Yazici, Aysegul Erinc, Celal Satici
    Future Oncology.2025; : 1.     CrossRef
  • Brain Metastasis of Non-small Cell Lung Cancer After Disease-Free Survival of 5 years: Case Series and Comprehensive Literature Review
    Takahiro Suzuki, Shoichi Deguchi, Keigo Matsushima, Shinya Katsumata, Hideaki Kojima, Maeda Koki, Hayato Konno, Mitsuhiro Isaka, Takuma Oishi, Yasuhisa Ohde, Takashi Sugino, Koichi Mitsuya, Nakamasa Hayashi
    World Neurosurgery.2024; 186: e353.     CrossRef
  • Complex situations in lung cancer: multifocal disease, oligoprogression and oligorecurrence
    Raphael Werner, Nina Steinmann, Herbert Decaluwe, Hiroshi Date, Dirk De Ruysscher, Isabelle Opitz
    European Respiratory Review.2024; 33(172): 230200.     CrossRef
  • 6,611 View
  • 158 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
Case Report
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Sehhoon Park, Bo Mi Ku, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Se-Hoon Lee, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2020;52(4):1288-1290.   Published online June 22, 2020
DOI: https://doi.org/10.4143/crt.2020.278
AbstractAbstract PDFPubReaderePub
The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as a standard treatment option. In this study, we are reporting the first case of resistance mechanism to the novel third-generation EGFR TKI, lazertinib, which showed promising clinical efficacy in phase 1-2 study. The patients showed resistance to the treatment by acquiring the additional EGFR C797S mutation in cis which is also confirmed from the patient-derived cell lines.

Citations

Citations to this article as recorded by  
  • Research Advances of Small Molecule EGFR-TKIs in NSCLC
    亚南 胡
    Pharmacy Information.2024; 13(01): 1.     CrossRef
  • An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review
    Prasad Sanjay Dhiwar, Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, Ekta Singh, Abhishek Ghara, Lalmohan Maji, Sindhuja Sengupta, Ganesh Andhale
    Journal of Biomolecular Structure and Dynamics.2024; 42(3): 1564.     CrossRef
  • The efficacy of almonertinib and anlotinib combination therapy for advanced non‐small‐cell lung cancer patients who continued to experience cancer progression during third‐generation EGFR‐TKI treatment: a retrospective study
    Yu Zhang, Chengmeng Wang, Jing Zhao, Meng Wang
    Thoracic Cancer.2024; 15(23): 1757.     CrossRef
  • Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review
    Yue Fang, Qiankun Zhang, Weimin Wang, Juanjuan Tong, Xialin Li
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure–Activity Relationship
    Tanuja T. Yadav, Gulam Moin Shaikh, Maushmi S. Kumar, Meena Chintamaneni, Mayur YC
    Frontiers in Chemistry.2022;[Epub]     CrossRef
  • Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)
    David E. Heppner, Florian Wittlinger, Tyler S. Beyett, Tatiana Shaurova, Daniel A. Urul, Brian Buckley, Calvin D. Pham, Ilse K. Schaeffner, Bo Yang, Blessing C. Ogboo, Earl W. May, Erik M. Schaefer, Michael J. Eck, Stefan A. Laufer, Pamela A. Hershberger
    ACS Medicinal Chemistry Letters.2022; 13(12): 1856.     CrossRef
  • Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
    Kyu Sic You, Yong Weon Yi, Jeonghee Cho, Jeong-Soo Park, Yeon-Sun Seong
    Pharmaceuticals.2021; 14(6): 589.     CrossRef
  • Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
    Sehhoon Park, Chung Lee, Bo Mi Ku, Minjae Kim, Woong-Yang Park, Nayoung K. D. Kim, Myung-Ju Ahn
    BMB Reports.2021; 54(7): 386.     CrossRef
  • 8,774 View
  • 347 Download
  • 23 Web of Science
  • 8 Crossref
Close layer
Original Articles
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
Kangkook Lee, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2020;52(1):292-300.   Published online July 26, 2019
DOI: https://doi.org/10.4143/crt.2019.186
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Human epidermal growth factor receptor 2 (HER2) alterations are found in approximately 1%-3% of non-small cell lung cancers (NSCLCs). We evaluated the clinical features and outcomes of NSCLC harboring HER2 alteration detected by next-generation sequencing (NGS) in Korea.
Materials and Methods
A total of 1,108 patients who were diagnosed with NSCLC between December 2015 and December 2017 were screened and analyzed by NGS. Medical records were reviewed retrospectively to analyze the clinical characteristics and outcomes from various treatments.
Results
HER2 alterations were identified in 36 NSCLC patients. Of the patients, 22 (61.1%) had an exon 20 in-frame insertion mutation, 15 (41.7%) had HER2 amplification, and one had both. The median patient age was 58 years, 55.6% were male, and 50.0% were never-smokers. Adenocarcinoma was predominant (88.9%). The most common metastatic site was bone (58.3%), and 66.7% of patients were stage IV at initial diagnosis. Six patients (16.7%) had a coexistent sensitizing epidermal growth factor receptor (EGFR) mutation, and two patients (5.6%) had anaplastic lymphoma kinase (ALK) rearrangement. With a median 14 months of follow-up, the median progression-free survival of first-line treatment was 6 months (95% confidence interval, 4.172 to 7.828), and median overall survival was not reached. The proportions of adenocarcinoma, never-smokers, and metastasis to the liver were higher in the exon 20 in-frame insertion mutation group, whereas coexistence of EGFR mutation was more frequently found in the HER2 amplification group.
Conclusion
HER2-altered NSCLC showed distinct clinical features. Moreover, different characteristics were identified between the HER2 in-frame insertion mutation group and the HER2 amplification group.

Citations

Citations to this article as recorded by  
  • Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges
    Jeong Uk Lim, Junyang Jung, Yeon Wook Kim, Chi Young Kim, Sang Hoon Lee, Dong Won Park, Sue In Choi, Wonjun Ji, Chang Dong Yeo, Seung Hyeun Lee
    Biomedicines.2025; 13(2): 470.     CrossRef
  • Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non–Small Cell Lung Cancer: Implications for Precision Medicine
    Yurimi Lee, Boram Lee, Yoon-La Choi, Dong-Wook Kang, Joungho Han
    Modern Pathology.2024; 37(6): 100490.     CrossRef
  • The frequency of EGFR gene mutations in a cohort of Romanian patients with non-small cell lung cancer and their association with PD-L1 expression level and ALK rearrangements
    Ester-Andreea Cohn, Ortansa Csutak, Ecaterina Tataru
    Revista Romana de Medicina de Laborator.2024; 32(3): 237.     CrossRef
  • Antibody–Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases
    David J. H. Bian, Sara F. Cohen, Anna-Maria Lazaratos, Nathaniel Bouganim, Matthew Dankner
    Current Oncology.2024; 31(10): 6314.     CrossRef
  • ERBB2 mutation landscape in non-small cell lung cancer patients in Northeast China
    Hui Li, Xiang Li, Shaowei Lan, Xuerong Zuo, Tianying Du, Ying Liu, Caixia Zhang, Jing Zhu, Ying Cheng
    Tumori Journal.2023; 109(3): 276.     CrossRef
  • Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations
    Xiaoli Zhuo, Honglin Guo, Jun Ma, Jingjiang Lai, Lei Liu, Ke Yin, Jing Zhao, Jingliang Wang, Fengxian Jiang, Wei Xu, Xiaotian Yuan, Xiaoyan Lin, Guobin Fu
    Journal of Cancer Research and Clinical Oncology.2023; 149(5): 2029.     CrossRef
  • Real World Characteristics and Clinical Outcomes of HER2-Mutant Non–Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
    Beung-Chul Ahn, Ye-Jeong Han, Hye Ryun Kim, Min Hee Hong, Byoung Chul Cho, Sun Min Lim
    Cancer Research and Treatment.2023; 55(2): 488.     CrossRef
  • Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients
    Ola Abu Al Karsaneh, Arwa Al Anber, Mohammad ALQudah, Sahar Al-Mustafa, Hussien AlMa’aitah, Maher Sughayer
    Diagnostic Pathology.2023;[Epub]     CrossRef
  • Exploring the correlation between HER2 alterations and 18F-FDG PET/CT metabolic parameters and their prognostic value in EGFR-negative non-small-cell lung cancer patients
    Maomei Ruan, Cheng Chang, Jianwen Sun, Liu Liu, Lihua Wang, Bei Lei, Hui Yan, He Zhang, Wenhui Xie, Yuetao Wang
    Journal of Cancer Research and Clinical Oncology.2023; 149(16): 14493.     CrossRef
  • Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
    Zhengbo Song, Dongqing Lv, Shi-Qing Chen, Jianjin Huang, Yuping Li, Shenpeng Ying, Xiaoyu Wu, Feng Hua, Wenxian Wang, Chunwei Xu, Ting Bei, Chan Gao, Zhijian Sun, Yiping Zhang, Shun Lu
    Clinical Cancer Research.2022; 28(3): 461.     CrossRef
  • Consensus for HER2 alterations testing in non-small-cell lung cancer
    S. Ren, J. Wang, J. Ying, T. Mitsudomi, D.H. Lee, Z. Wang, Q. Chu, P.C. Mack, Y. Cheng, J. Duan, Y. Fan, B. Han, Z. Hui, A. Liu, J. Liu, Y. Lu, Z. Ma, M. Shi, Y. Shu, Q. Song, X. Song, Y. Song, C. Wang, X. Wang, Z. Wang, Y. Xu, Y. Yao, L. Zhang, M. Zhao,
    ESMO Open.2022; 7(1): 100395.     CrossRef
  • Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches
    Christophe Bontoux, Jonathan Benzaquen, Véronique Hofman, Simon Heeke, Paul Hannetel, Pierre Capela-Brosseau-Laborde, Charles-Hugo Marquette, Marius Ilié, Paul Hofman
    Journal of Personalized Medicine.2022; 12(10): 1651.     CrossRef
  • Predictors for survival in patients with bone metastasis of small cell lung cancer
    MingFeng Xue, Gang Chen, XingGuang Chen, JunYu Hu
    Medicine.2021; 100(34): e27070.     CrossRef
  • Advances in systemic therapy for non-small cell lung cancer
    Meagan Miller, Nasser Hanna
    BMJ.2021; : n2363.     CrossRef
  • Genetic Markers in Lung Cancer Diagnosis: A Review
    Katarzyna Wadowska, Iwona Bil-Lula, Łukasz Trembecki, Mariola Śliwińska-Mossoń
    International Journal of Molecular Sciences.2020; 21(13): 4569.     CrossRef
  • Exploration of estrogen receptor‑associated hub genes and potential molecular mechanisms in non‑smoking females with lung adenocarcinoma using integrated bioinformatics analysis
    Hao Wang, Zhihong Zhang, Ke Xu, Song Wei, Lailing Li, Lijun Wang
    Oncology Letters.2019;[Epub]     CrossRef
  • 10,072 View
  • 390 Download
  • 21 Web of Science
  • 16 Crossref
Close layer
Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer
Kyung Hwa Lee, Yong Chan Ahn, Hongryull Pyo, Jae Myoung Noh, Seung Gyu Park, Tae Gyu Kim, Eonju Lee, Heerim Nam, Hyebin Lee, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park
Cancer Res Treat. 2019;51(2):769-776.   Published online September 11, 2018
DOI: https://doi.org/10.4143/crt.2018.366
AbstractAbstract PDFPubReaderePub
Purpose
This study is to report clinical outcomes of salvage concurrent chemo-radiation therapy (CCRT) in treating patients with loco-regional recurrence (LRR) following initial complete resection of non-small cell lung cancer.
Materials and Methods
Between February 2004 and December 2016, 127 patients underwent salvage CCRT for LRR. The median radiation therapy (RT) dose was 66 Gy and clinical target volume was to cover recurrent lesion with margin without elective inclusion of regional lymphatics. Majority of patients (94.5%) received weekly platinum-based doublet chemotherapy during RT course.
Results
The median follow-up time from the start of CCRT was 25 months. The median survival duration was 49 months, and overall survival (OS) rates at 2 and 5 years were 72.9% and 43.9%. The 2- and 5-year rates of in-field failure-free survival, distant metastasis free survival, and progression free survival were 82.4% and 73.8%, 50.4% and 39.9%, and 34.6% and 22.3%, respectively. Grade ≥ 3 radiation-related esophagitis and pneumonitis occurred in 14 (11.0%) and six patients (4.7%), respectively. On both univariate and multivariate analysis, higher biologically equivalent dose (BED10) (≥ 79.2 Gy10 vs. < 79.2 Gy10; hazard ratio [HR], 0.431), smaller CTV (≤ 80 cm3 vs. > 80 cm3; HR, 0.403), and longer disease-free interval (> 1 year vs. ≤ 1 year; HR, 0.489) were significantly favorable factors for OS.
Conclusion
The current study has demonstrated that high dose salvage CCRT focused to the involved lesion only was highly effective and safe. In particular, higher BED10, smaller CTV, and longer disease-free interval were favorable factors for improved survival.

Citations

Citations to this article as recorded by  
  • Prognosis of non‐small cell lung cancer with postoperative regional lymph node recurrence
    Yoichi Ohtaki, Toshiteru Nagashima, Naoko Okano, Nobuteru Kubo, Takeru Ohtaka, Noriaki Sunaga, Reiko Sakurai, Yosuke Miura, Seshiru Nakazawa, Natsuko Kawatani, Tomohiro Yazawa, Ryohei Yoshikawa, Eiji Narusawa, Ken Shirabe
    Thoracic Cancer.2024; 15(11): 859.     CrossRef
  • Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non–small‐cell lung cancer (NEJ056)
    Megumi Furuta, Hidehito Horinouchi, Isao Yokota, Teppei Yamaguchi, Shoichi Itoh, Takafumi Fukui, Akira Iwashima, Jun Sugisaka, Yu Miura, Hisashi Tanaka, Taichi Miyawaki, Hiroshi Yokouchi, Keita Miura, Ryota Saito, Go Saito, Tatsuhiko Kamoshida, Yusuke Uch
    Cancer Science.2024; 115(11): 3705.     CrossRef
  • Impact of lymphadenectomy extent on immunotherapy efficacy in post-resectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study
    Hongsheng Deng, Juan Zhou, Hualin Chen, Xiuyu Cai, Ran Zhong, Feng Li, Bo Cheng, Caichen Li, Qingzhu Jia, Caicun Zhou, René Horsleben Petersen, Gaetano Rocco, Alex Brunelli, Calvin S.H. Ng, Thomas A. D’Amico, Chunxia Su, Jianxing He, Wenhua Liang, Bo Zhu
    International Journal of Surgery.2023;[Epub]     CrossRef
  • Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence
    Kathleen Bowes, Nick Jovanoski, Audrey E. Brown, Danilo Di Maio, Rossella Belleli, Shkun Chadda, Seye Abogunrin
    Medical Oncology.2022;[Epub]     CrossRef
  • Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer
    Hyunju Shin, Jae Myoung Noh, Hongryull Pyo, Yong Chan Ahn, Dongryul Oh
    Radiation Oncology Journal.2021; 39(1): 24.     CrossRef
  • Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017)
    NaiBin Chen, QiWen Li, SiYu Wang, Mai Xiong, YiFeng Luo, Bin Wang, Li Chen, MaoSheng Lin, XiaoBo Jiang, JianLan Fang, SuPing Guo, JinYu Guo, Nan Hu, XinLei Ai, DaQuan Wang, Chu Chu, FangJie Liu, Hao Long, JunYe Wang, Bo Qiu, Hui Liu
    Lung Cancer.2021; 156: 82.     CrossRef
  • Salvage radiation therapy for postoperative locoregionally recurrent non-small cell lung cancer: a single-center experience
    Yoon Young Jo, Su Ssan Kim, Si Yeol Song, Eun Kyung Choi
    Radiation Oncology Journal.2021; 39(3): 210.     CrossRef
  • Propensity score adjusted analysis of patients with isolated locoregional recurrence versus de novo locally advanced NSCLC treated with definitive therapy
    Cole Friedes, Nicholas Mai, Wei Fu, Chen Hu, Peijin Han, Kristen A. Marrone, K. Ranh Voong, Russell K. Hales
    Lung Cancer.2020; 145: 119.     CrossRef
  • 9,863 View
  • 226 Download
  • 10 Web of Science
  • 8 Crossref
Close layer
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon-Gu Kim, Heui June Ahn, Ha Yeon Lee, Hwan Jung Yun, Jin-Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):718-726.   Published online September 3, 2018
DOI: https://doi.org/10.4143/crt.2018.324
AbstractAbstract PDFPubReaderePub
Purpose
The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
Materials and Methods
We conducted a multi-center randomized phase II trial to compare the clinical outcomes between pemetrexed plus cisplatin combination therapy followed by maintenance pemetrexed (PC) and pemetrexed monotherapy (P) after failure of first-line EGFR-TKI. The primary objective was progression-free survival (PFS), and secondary objectives included overall response rate (ORR), overall survival (OS), health-related quality of life (HRQOL), and safety and toxicity profiles.
Results
A total of 96 patientswere randomized, and 91 patientswere treated at 14 centers in Korea. The ORR was 34.8% (16/46) for the PC arm and 17.8% (8/45) for the P arm (p=0.066). With 23.4 months of follow-up, the median PFS was 5.4 months in the PC arm and 6.4 months in the P arm (p=0.114). The median OS was 17.9 months and 15.7 months in PC and P arms, respectively (p=0.787). Adverse events ≥ grade 3 were reported in 12 patients (26.1%) in the PC arm and nine patients (20.0%) in the P arm (p=0.491). The overall time trends of HRQOL were not significantly different between the two arms.
Conclusion
The outcomes of pemetrexed therapy in NSCLC patients with disease progression after firstline EGFR-TKI might not be improved by adding cisplatin.

Citations

Citations to this article as recorded by  
  • The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
    Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
    Cancer Research and Treatment.2025; 57(1): 39.     CrossRef
  • A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial
    R.A. Soo, K. Vervita, M. Früh, B.C. Cho, M. Majem, D. Rodriguez Abreu, K. Ribi, A. Callejo, T. Moran, M. Domine Gomez, M. Provencio, A. Addeo, J.Y. Han, A.L. Ortega Granados, M. Reck, A. Blasco, R. Garcia Campelo, M.A. Sala González, C. Britschgi, H. Rosc
    Lung Cancer.2025; 202: 108454.     CrossRef
  • Osimertinib with Chemotherapy in EGFR -Mutated NSCLC

    New England Journal of Medicine.2024; 390(5): 478.     CrossRef
  • Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors
    Balazs Halmos, Pragya Rai, Jae Min, Xiaohan Hu, Diana Chirovsky, Mark Shamoun, Bin Zhao
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma
    Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
    Asia-Pacific Journal of Clinical Oncology.2023; 19(1): 87.     CrossRef
  • Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment
    Cheng-Yu Chang, Chung-Yu Chen, Shih-Chieh Chang, Ching-Yi Chen, Yi-Chun Lai, Chun-Fu Chang, Yu-Feng Wei
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class
    Joseph N. Samuel, Christopher M. Booth, Elizabeth Eisenhauer, Michael Brundage, Scott R. Berry, Bishal Gyawali
    JAMA Oncology.2022; 8(6): 879.     CrossRef
  • Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
    Ruizhu Sun, Zhansheng Hou, Yankui Zhang, Bo Jiang
    Oncology Letters.2022;[Epub]     CrossRef
  • Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid
    Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
    Lung Cancer.2021; 152: 15.     CrossRef
  • Exploring the role of epidermal growth factor receptor variant III in meningeal tumors
    Rashmi Rana, Vaishnavi Rathi, Kirti Chauhan, Kriti Jain, Satnam Singh Chhabra, Rajesh Acharya, Samir Kumar Kalra, Anshul Gupta, Sunila Jain, Nirmal Kumar Ganguly, Dharmendra Kumar Yadav, Timir Tripathi
    PLOS ONE.2021; 16(9): e0255133.     CrossRef
  • Risk factors of nephrotoxicity of maintenance pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung
    Wang Chun Kwok, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
    Lung Cancer.2021; 162: 169.     CrossRef
  • Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
    Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
    Current Oncology.2021; 28(6): 4894.     CrossRef
  • Real world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma
    Wang Chun Kwok, David Chi Leung Lam, Ka Yan Chiang, James Chung Man Ho, Mary Sau Man Ip, Terence Chi Chun Tam
    Journal of Chemotherapy.2020; 32(8): 429.     CrossRef
  • 10,611 View
  • 355 Download
  • 15 Web of Science
  • 13 Crossref
Close layer
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Seonggyu Byeon, Youjin Kim, Sung Won Lim, Jang Ho Cho, Sehoon Park, Jiyun Lee, Jong-Mu Sun, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):623-631.   Published online July 23, 2018
DOI: https://doi.org/10.4143/crt.2018.151
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for approximately 4% of all EGFR mutations. Given the rarity of this mutation, its clinical outcomes are not fully established.
Materials and Methods
Between 2009 and 2017, non-small cell lung cancer (NSCLC) patients who showed an exon 20 insertion were retrospectively reviewed for clinical characteristics and outcomes, including responses to chemotherapy (CTx) or targeted therapy.
Results
Of 3,539 NSCLC patients who harbored an activating EGFR mutation, 56 (1.6%) had an exon 20 insertion. Of the advanced NSCLC patients, 27 of 1,479 (1.8%) had an exon 20 insertion. The median overall survival was 29.4 months (95% confidence interval 9.3 to 49.6) for 27 advancedNSCLC patients. The 22 patientswho received systemic CTx achieved a 50.0% response rate and a 77.2% disease control rate, with 4.2 months of progressionfree survival. Six patients received EGFR tyrosine kinase inhibitors (TKIs). Three of the four patients that had only an exon 20 insertion showed progressive disease, while one showed stable disease. The othertwo patients had an exon 20 insertion and another EGFR mutation and achieved a partial response.
Conclusion
The incidence of an exon 20 insertion mutation is rare in Korea and occasionally accompanied by other common EGFR mutations. Although the response to systemic CTx. in these patients is comparable to that of patients with other mutations, the response rate to firstor second-generation EGFR TKIs is quite low. Therefore, the development of a more efficient agent is urgently needed.

Citations

Citations to this article as recorded by  
  • First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
    Pasi A. Jänne, Bin-Chao Wang, Byoung Chul Cho, Jun Zhao, Juan Li, Maximilian Hochmair, Solange Peters, Benjamin Besse, Nick Pavlakis, Joel W. Neal, Terufumi Kato, Yi-Long Wu, Danny Nguyen, Junjing Lin, Jianchang Lin, Florin Vranceanu, Annette Szumski, Hua
    Journal of Clinical Oncology.2025; 43(13): 1553.     CrossRef
  • The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of EGFR exon 20: A retrospective analysis
    Ke-Jun Liu, Hong-Rui Li, Quan-Quan Tan, Tao Jiang, Kai-Cheng Peng, Hua-Jun Chen, Qing Zhou, Xu-Chao Zhang, Zheng Zheng, Shi-Yuan Chen, Xue Zheng, Hong-Bo Zheng, Bei-Bei Mao, Long-Long Gong, Xian-Wen Chen, Wendy Wu, Yi-Long Wu, Jun Jia, Jin-Ji Yang
    Science Progress.2025;[Epub]     CrossRef
  • Advances in the Diagnosis and Treatment of Advanced Non–Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
    Jingwen Liu, Yan Xiang, Tingwen Fang, Lulin Zeng, Ao Sun, Yixiang Lin, Kaihua Lu
    Clinical Lung Cancer.2024; 25(2): 100.     CrossRef
  • Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
    Maximilian J. Hochmair, Mojca Unk, Jelena Spasic, Timur Cerić, Assia Konsoulova, Mircea Dediu, Krisztina Bogos, Alinta Hegmane, Kersti Oselin, Marko Stojiljkovic, Tina Roblek, Marko Jakopovic
    BMC Proceedings.2024;[Epub]     CrossRef
  • Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia
    Masanobu Okahisa, Hibiki Udagawa, Shingo Matsumoto, Terufumi Kato, Hiroshi Yokouchi, Naoki Furuya, Ryota Kanemaru, Ryo Toyozawa, Akihiro Nishiyama, Kadoaki Ohashi, Shingo Miyamoto, Kazumi Nishino, Atsushi Nakamura, Eiji Iwama, Seiji Niho, Hajime Oi, Tetsu
    Lung Cancer.2024; 191: 107798.     CrossRef
  • The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation
    Xiuyue Man, Xueru Sun, Chen Chen, Yan Xiang, Jing Zhang, Lei Yang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
    Pınar Gursoy, Ali Murat Tatli, Dilek Erdem, Erdem Goker, Emir Celik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atci, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici, Baran Akangunduz, Sevinç Balli, Ahmet Demirkazik, Fatih Selçukb
    Journal of Cancer Research and Clinical Oncology.2023; 149(2): 865.     CrossRef
  • Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison
    Sai-Hong I. Ou, Huamao M. Lin, Jin-Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Pingkuan Zhang, Danny Nguyen, Joel W. Neal
    Lung Cancer.2023; 179: 107186.     CrossRef
  • EGFR and ERBB2 exon 20 insertion/duplication in advanced non–small cell lung cancer: genomic profiling and clinicopathologic features
    Ramakrishna R. Sompallae, Bilge Dundar, Natalya V. Guseva, Aaron D. Bossler, Deqin Ma
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions
    Ying-Ting Liao, Lei-Chi Wang, Ruei-Lin Sun, Yi-Chen Yeh, Hsu-Ching Huang, Chia-I Shen, Yen-Han Tseng, Tsu-Hui Hsiao, Heng-Sheng Chao, Yung-Hung Luo, Yuh-Min Chen, Chi-Lu Chiang
    Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10365.     CrossRef
  • EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies
    Qianming Bai, Jialei Wang, Xiaoyan Zhou
    Cancer Treatment Reviews.2023; 120: 102605.     CrossRef
  • A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments
    Fenneke Zwierenga, Bianca A.M.H. van Veggel, Anke van den Berg, Harry J.M. Groen, Lili Zhang, Matthew R. Groves, K. Kok, E.F. Smit, T. Jeroen N. Hiltermann, Adrianus J. de Langen, Anthonie J. van der Wekken
    Cancer Treatment Reviews.2023; 120: 102628.     CrossRef
  • Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer
    Binyang Pan, Jiaqi Liang, Haochun Shi, Kungeng Rao, Weigang Guo, Cheng Zhan
    Thoracic Cancer.2023; 14(33): 3247.     CrossRef
  • Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report
    Youjun Deng, Chenglin Yang, Wenyi Liu, Songhua Cai, Xiaotong Guo
    Anti-Cancer Drugs.2022; 33(4): 406.     CrossRef
  • Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer
    Neeraj Gupta, Philippe B. Pierrillas, Michael J. Hanley, Steven Zhang, Paul M. Diderichsen
    CPT: Pharmacometrics & Systems Pharmacology.2022; 11(6): 731.     CrossRef
  • Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
    Timothée Olivier, Vinay Prasad
    Translational Oncology.2022; 23: 101475.     CrossRef
  • Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
    Yasir Y. Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrao, Monique B. Nilsson, Anisha Patel, R.S.K. Vijayan, Jason B. Cross, Jianjun Zhan
    Cancer Cell.2022; 40(7): 754.     CrossRef
  • EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors
    Guangjian Yang, Yaning Yang, Jiaqi Hu, Haiyan Xu, Shuyang Zhang, Yan Wang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis
    Ainur F. Nasretdinov, Konstantin V. Menshikov, Alexander V. Sultanbaev, Shamil I. Musin, Nadezda I. Sultanbaeva, Irina A. Men'shikova
    Journal of Modern Oncology.2022; 24(3): 340.     CrossRef
  • Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
    Maria Garcia Campelo, Caicun Zhou, Suresh Ramalingam, Huamao Lin, Tae Kim, Gregory Riely, Tarek Mekhail, Danny Nguyen, Erin Goodman, Minal Mehta, Sanjay Popat, Pasi Jänne
    Journal of Clinical Medicine.2022; 12(1): 112.     CrossRef
  • Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations
    Guang-Jian Yang, Jun Li, Hai-Yan Xu, Yang Sun, Liu Liu, Hong-Shuai Li, Lu Yang, Yuan Zhang, Guo-Hui Li, Yan Wang
    Lung Cancer.2021; 152: 39.     CrossRef
  • Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review
    Heather Burnett, Helena Emich, Chris Carroll, Naomi Stapleton, Parthiv Mahadevia, Tracy Li, Rama Krishna Kancha
    PLOS ONE.2021; 16(3): e0247620.     CrossRef
  • Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions
    Noura J. Choudhury, Adam J. Schoenfeld, Jessica Flynn, Christina J. Falcon, Hira Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena A. Yu, Marc Ladanyi, Gregory J. Riely
    Clinical Cancer Research.2021; 27(10): 2920.     CrossRef
  • EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer
    Jose Luis Leal, Marliese Alexander, Malinda Itchins, Gavin M. Wright, Steven Kao, Brett G.M. Hughes, Nick Pavlakis, Stephen Clarke, Anthony J Gill, Hannah Ainsworth, Benjamin Solomon, Thomas John
    Clinical Lung Cancer.2021; 22(6): e859.     CrossRef
  • Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
    Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazhenova, Viola W. Zhu, Howard L. West, Tarek Mekhail, Ryan D. Gentzler, Danny Nguyen, Sylv
    Cancer Discovery.2021; 11(7): 1688.     CrossRef
  • Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
    Chie Morita, Tatsuya Yoshida, Masayuki Shirasawa, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Shigehiro Yagishita, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Noriko Motoi, Yasushi Yatabe, Yuichiro Ohe
    Scientific Reports.2021;[Epub]     CrossRef
  • EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
    Samy Chelabi, Xavier Mignard, Karen Leroy, Isabelle Monnet, Solenn Brosseau, Nathalie Theou-Anton, Marie-Ange Massiani, Sylvie Friard, Boris Duchemann, Elizabeth Fabre, Etienne Giroux-Leprieur, Jacques Cadranel, Marie Wislez
    Cancers.2021; 13(20): 5132.     CrossRef
  • Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
    Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim, Sang-We Kim, James Chih-Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, Maria R. Garcia Campelo, Enriqueta Felip, Sylvie Vincent, Shu Jin, Celina Griffin, Veronica Bunn, Jianchang Lin, Huamao M. Li
    JAMA Oncology.2021; 7(12): e214761.     CrossRef
  • A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
    Christos Chouaid, Thomas Filleron, Didier Debieuvre, Maurice Pérol, Nicolas Girard, Eric Dansin, Hervé Lena, Radj Gervais, Sophie Cousin, Josiane Otto, Roland Schott, David Planchard, Anne Madroszyk, Courèche Kaderbhai, Pascale DUBRAY-Longeras, Sandrine H
    Targeted Oncology.2021; 16(6): 801.     CrossRef
  • External Quality Assurance of Current Technology for the Testing of Cancer-Associated Circulating Free DNA Variants
    Sze Yee Chai, Rongxue Peng, Rui Zhang, Li Zhou, Nalishia Pillay, Kwang Hong Tay, Tony Badrick, Jinming Li, Martin P. Horan
    Pathology & Oncology Research.2020; 26(3): 1595.     CrossRef
  • Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
    B. van Veggel, J.F. Vilacha Madeira R Santos, S.M.S. Hashemi, M.S. Paats, K. Monkhorst, D.A.M. Heideman, M. Groves, T. Radonic, E.F. Smit, E. Schuuring, A.J. van der Wekken, A.J. de Langen
    Lung Cancer.2020; 141: 9.     CrossRef
  • EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
    Guangjian Yang, Jun Li, Haiyan Xu, Yaning Yang, Lu Yang, Fei Xu, Bing Xia, Viola W. Zhu, Misako Nagasaka, Yan Yang, Yapin Li, Weini Qiu, Jianming Ying, Sai-Hong Ignatius Ou, Yan Wang
    Lung Cancer.2020; 145: 186.     CrossRef
  • Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
    YanRu Qin, Hong Jian, Xiaoling Tong, Xue Wu, Fufeng Wang, Yang W. Shao, Xinmin Zhao
    Molecular Oncology.2020; 14(8): 1695.     CrossRef
  • The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
    Shang-Gin Wu, Chong-Jen Yu, James Chih-Hsin Yang, Jin-Yuan Shih
    Therapeutic Advances in Medical Oncology.2020;[Epub]     CrossRef
  • Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India
    Varsha Singh, Aruna Nambirajan, Prabhat Singh Malik, Sanjay Thulkar, Ravindra Mohan Pandey, Kalpana Luthra, Sudheer Arava, Ruma Ray, Anant Mohan, Deepali Jain
    Lung Cancer.2020; 149: 53.     CrossRef
  • Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations
    Jenn-Yu Wu, Chong-Jen Yu, Jin-Yuan Shih
    Clinical Lung Cancer.2019; 20(6): e620.     CrossRef
  • Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
    J. Chantharasamee, N. Poungvarin, P. Danchaivijitr, S. Techawatanawanna
    BMC Cancer.2019;[Epub]     CrossRef
  • Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
    Ya Gao, Wies R. Vallentgoed, Pim J. French
    Cancers.2018; 10(12): 489.     CrossRef
  • 16,976 View
  • 714 Download
  • 44 Web of Science
  • 38 Crossref
Close layer
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
Song Ee Park, Jae Myoung Noh, You Jin Kim, Han Sang Lee, Jang Ho Cho, Sung Won Lim, Yong Chan Ahn, Hongryull Pyo, Yoon-La Choi, Joungho Han, Jong-Mu Sun, Se Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):493-501.   Published online June 18, 2018
DOI: https://doi.org/10.4143/crt.2018.125
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to evaluate the relationship between epidermal growth factor receptor (EGFR) mutation and clinical outcomes in patients with stage III non-squamous cell lung cancer treated with definitive concurrent chemoradiotherapy (CCRT).
Materials and Methods
From January 2008 to December 2013, the medical records of 197 patients with stage III non- squamous non-small cell lung cancer treated with definitive CCRT were analyzed to determine progression-free survival (PFS) and overall survival (OS) according to EGFR mutation status.
Results
Among 197 eligible patients, 81 patients were EGFR wild type, 36 patients had an EGFR mutation (exon 19 Del, n=18; L858R, n=9, uncommon [G719X, L868, T790M], n=9), and 80 patients had unknown EGFR status. The median age was 59 years (range, 28 to 80 years) and 136 patients (69.0%) were male. The median follow-up duration was 66.5 months (range, 1.9 to 114.5 months). One hundred sixty-four patients (83.2%) experienced disease progression. Median PFS was 8.9 months for the EGFR mutation group, 11.8 months for EGFR wild type, and 10.5 months for the unknown EGFR group (p=0.013 and p=0.042, respectively). The most common site of metastasis in the EGFR mutant group was the brain. However, there was no significant difference in OS among the three groups (34.6 months for EGFR mutant group vs. 31.9 months for EGFR wild type vs. 22.6 months for EGFR unknown group; p=0.792 and p=0.284). A total of 29 patients (80.6%) with EGFR mutation were treated with EGFR tyrosine kinase inhibitor (gefitinib, n=24; erlotinib, n=3; afatinib, n=2) upon progression.
Conclusion
EGFR mutation is associatedwith short PFS and the brain is the most common site of distant metastasis in patients with stage III non- squamous cell lung cancer treated with CCRT.

Citations

Citations to this article as recorded by  
  • Economic Burden and Provider Referral Patterns Among Patients with Unresectable Stage III EGFR-Mutated NSCLC Receiving Chemoradiotherapy in the United States
    YongJin Kim, Yong Zhu, Kristin J. Moore, Mary DuCharme, Dan James, Arber Shehu, Yanique Rattigan-Brown, Kim Ohaegbulam
    Advances in Therapy.2025;[Epub]     CrossRef
  • Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee
    Sarah Bowen Jones, Clara Chan, Andrea R. Filippi, Ken Harada, Alexander V. Louie, Colin R. Lindsay, Ernest Nadal, Pablo Munoz Schuffenegger, David Woolf, Corinne Faivre-Finn
    Journal of Thoracic Oncology.2025;[Epub]     CrossRef
  • Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
    Terufumi Kato, Ignacio Casarini, Manuel Cobo, Corinne Faivre-Finn, Fiona Hegi-Johnson, Shun Lu, Mustafa Özgüroğlu, Suresh S. Ramalingam
    Lung Cancer.2024; 187: 107414.     CrossRef
  • Treatment patterns and survival analysis in patients with unresectable stage III EGFR-mutated non-small cell lung cancer
    Huan-Wei Liang, Yang Liu, Xin-Bin Pan
    Aging.2024;[Epub]     CrossRef
  • Durvalumab after chemoradiotherapy in non‐small cell lung cancer with EGFR mutation: A real‐world study (HOT2101)
    Kosuke Tsuji, Hidenori Mizugaki, Keiki Yokoo, Maki Kobayashi, Yosuke Kawashima, Nozomu Kimura, Hiroshi Yokouchi, Hajime Kikuchi, Toshiyuki Sumi, Yasutaka Kawai, Kenta Kobashi, Ryo Morita, Kenichiro Ito, Yasuo Kitamura, Hiroyuki Minemura, Keiichi Nakamura,
    Cancer Science.2024; 115(4): 1273.     CrossRef
  • Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
    Amin H. Nassar, So Yeon Kim, Jacqueline V. Aredo, Jamie Feng, Frances Shepherd, Chao Xu, David Kaldas, Jhanelle E. Gray, Thomas J. Dilling, Joel W. Neal, Heather A. Wakelee, Yufei Liu, Steven H. Lin, Tariq Abuali, Arya Amini, Yunan Nie, Tejas Patil, Anast
    Journal of Thoracic Oncology.2024; 19(6): 928.     CrossRef
  • Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers
    David J. Stewart, Katherine Cole, Dominick Bosse, Stephanie Brule, Dean Fergusson, Tim Ramsay
    Current Oncology.2024; 31(3): 1600.     CrossRef
  • Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
    Shun Lu, Terufumi Kato, Xiaorong Dong, Myung-Ju Ahn, Le-Van Quang, Nopadol Soparattanapaisarn, Takako Inoue, Chih-Liang Wang, Meijuan Huang, James Chih-Hsin Yang, Manuel Cobo, Mustafa Özgüroğlu, Ignacio Casarini, Dang-Van Khiem, Virote Sriuranpong, Eduard
    New England Journal of Medicine.2024; 391(7): 585.     CrossRef
  • Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
    S. Lu, M.-J. Ahn, T. Reungwetwattana, M. Özgüroğlu, T. Kato, J.C.-H. Yang, M. Huang, F. Fujiki, T. Inoue, L.-V. Quang, V. Sriuranpong, D. Vicente, C. Fuentes, A.A. Chaudhry, L. Poole, E. Armenteros Monterroso, Y. Rukazenkov, T. van der Gronde, S.S. Ramali
    Annals of Oncology.2024; 35(12): 1116.     CrossRef
  • Comparison of treatment regimens for unresectable stage III epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer
    Xin Dai, Qian Xu, Lei Sheng, Xue Zhang, Miao Huang, Song Li, Kai Huang, Jiahui Chu, Jian Wang, Jisheng Li, Yanguo Liu, Jianyuan Zhou, Shulun Nie, Lian Liu
    Chinese Medical Journal.2024;[Epub]     CrossRef
  • Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy
    Jaewon Hyung, Hyunseok Yoon, Chang-Min Choi, Shinkyo Yoon, Dae Ho Lee, Sang-we Kim, Hyeong-ryul Kim, Su Ssan Kim, Si Yeol Song, Jae Cheol Lee
    Journal of Cancer Research and Clinical Oncology.2023; 149(8): 4243.     CrossRef
  • Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: A multi-center cohort study
    Nan Bi, Kunpeng Xu, Hong Ge, Ming Chen, Mingyan E, Li Zhang, Jianzhong Cao, Xu Zhang, Xiao Ding, Bing Xia, Lujun Zhao, Lijie Han, Jiancheng Li, Chen Hu, Luhua Wang
    Journal of the National Cancer Center.2023; 3(1): 65.     CrossRef
  • Locally Advanced Lung Cancer
    Sarah Oh, George N. Botros, Milan Patel, Missak Haigentz, Eshan Patel, Iaonnis Kontopidis, John Langenfeld, Matthew P. Deek, Salma K. Jabbour
    Hematology/Oncology Clinics of North America.2023; 37(3): 533.     CrossRef
  • Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations
    Ling Zhang, Yunhong You, Xueli Liu, Fengjuan Liu, Keke Nie, Youxin Ji
    Thoracic Cancer.2023; 14(15): 1355.     CrossRef
  • EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis
    Hongsik Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
    Cancer Research and Treatment.2023; 55(2): 498.     CrossRef
  • Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients
    Yang Liu, Huan-Wei Liang, Xin-Bin Pan
    Aging.2023;[Epub]     CrossRef
  • Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
    Sheng‐Yuan Wang, Ching‐Han Lai, Chian‐Wei Chen, Szu‐Chun Yang, Chao‐Chun Chang, Chia‐Ying Lin, Yi‐Ting Yen, Yau‐Lin Tseng, Po‐Lan Su, Chien‐Chung Lin, Wu‐Chou Su
    Thoracic Cancer.2022; 13(2): 182.     CrossRef
  • Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1‐STAT1 loop in lung adenocarcinoma
    Wei‐Chao Liao, Tsung‐Jen Lin, Yu‐Chin Liu, Yu‐Shan Wei, Guan‐Ying Chen, Hsiang‐Pu Feng, Yi‐Feng Chang, Hsin‐Tzu Chang, Chih‐Liang Wang, Hsinag‐Cheng Chi, Chun‐I Wang, Kwang‐Huei Lin, Wei‐Ting Ou Yang, Chia‐Jung Yu
    Cancer Science.2022; 113(1): 205.     CrossRef
  • An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
    Po-Lan Su, Gee-Chen Chang, Shih-Hsin Hsiao, Te-Chun Hsia, Meng-Chih Lin, Min-Hsi Lin, Jin-Yuan Shih, Cheng-Ta Yang, Sheng-Hsiung Yang, Yuh-Min Chen
    JTO Clinical and Research Reports.2022; 3(3): 100292.     CrossRef
  • Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study
    Yuxiang Wang, Wenjuan Yu, Jian Shi, Rong Qiu, Nan Jiang, Zhuofan Wang, Jie Yang, Zhongfei Jia, Meng Song
    Technology in Cancer Research & Treatment.2022;[Epub]     CrossRef
  • Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)
    Luis E. Raez, Oscar Arrieta, Diego F. Chamorro, Pamela Denisse Soberanis-Piña, Luis Corrales, Claudio Martín, Mauricio Cuello, Suraj Samtani, Gonzalo Recondo, Luis Mas, Zyanya Lucia Zatarain-Barrón, Alejandro Ruíz-Patiño, Juan Esteban García-Robledo, Cami
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion
    Yoonki Hong, Sunmin Park, Myoung Kyu Lee
    Scientific Reports.2022;[Epub]     CrossRef
  • First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia
    D. I. Yudin, K. K. Laktionov, F. V. Moiseenko, D. M. Ponomarenko, E. A. Chekh, V. A. Chubenko, N. V. Levchenko, V. V. Kozlov, E. О. Stepanova, K. A. Sarantseva, E. S. Denisova, M. S. Ardzinba, D. Yu. Yukalchuk
    Meditsinskiy sovet = Medical Council.2022; (22): 12.     CrossRef
  • Clinical outcomes and radiation pneumonitis after concurrent EGFR‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer
    Kunpeng Xu, Jun Liang, Tao Zhang, Zongmei Zhou, Dongfu Chen, Qinfu Feng, Zefen Xiao, Zhouguang Hui, Jima Lu, Xin Wang, Lei Deng, Wenyang Liu, Jianyang Wang, Yirui Zhai, Jie Wang, Nan Bi, Luhua Wang
    Thoracic Cancer.2021; 12(6): 814.     CrossRef
  • Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
    Jacqueline V. Aredo, Isa Mambetsariev, Jessica A. Hellyer, Arya Amini, Joel W. Neal, Sukhmani K. Padda, Caroline E. McCoach, Jonathan W. Riess, Elwyn C. Cabebe, Jarushka Naidoo, Tariq Abuali, Ravi Salgia, Billy W. Loo, Maximilian Diehn, Summer S. Han, Hea
    Journal of Thoracic Oncology.2021; 16(6): 1030.     CrossRef
  • Einfluss der Molekularpathologie auf die onkologische Chirurgie von Leber- und Gallengangstumoren
    Mazen A. Juratli, Benjamin Struecker, Shadi Katou, M. Haluk Morguel, Andreas Pascher
    Der Chirurg.2021; 92(11): 1003.     CrossRef
  • Locally Advanced, Unresectable Non-Small Cell Lung Cancer
    Sonam Puri, Andreas Saltos, Bradford Perez, Xiuning Le, Jhanelle E. Gray
    Current Oncology Reports.2020;[Epub]     CrossRef
  • Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
    Hyun Ae Jung, Jae Myoung Noh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Hongryull Pyo, Yong Chan Ahn, Keunchil Park
    Lung Cancer.2020; 146: 23.     CrossRef
  • Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
    Connor O’Leary, Harry Gasper, Katherine B. Sahin, Ming Tang, Arutha Kulasinghe, Mark N. Adams, Derek J. Richard, Ken J. O’Byrne
    Pharmaceuticals.2020; 13(10): 273.     CrossRef
  • MiRNAs: A New Approach to Predict and Overcome Resistance to Anticancer Drugs
    Noor Altaleb
    Clinical Cancer Drugs.2020; 7(2): 65.     CrossRef
  • Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations
    Bumhee Yang, Hyun Lee, Sang-Won Um, Kyunga Kim, Jae Il Zo, Young Mog Shim, O Jung Kwon, Kyung Soo Lee, Myung-Ju Ahn, Hojoong Kim
    Lung Cancer.2019; 129: 28.     CrossRef
  • A Prediction Rule for Overall Survival in Non-Small-Cell Lung Cancer Patients with a Pathological Tumor Size Less Than 30 mm
    Wang-Yu Zhu, Ke-xin Fang, Jian-ying He, Ri Cui, Yong-Kui Zhang, Han-bo Le
    Disease Markers.2019; 2019: 1.     CrossRef
  • 13,519 View
  • 475 Download
  • 30 Web of Science
  • 32 Crossref
Close layer
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
Youjin Kim, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jong-Mu Sun
Cancer Res Treat. 2019;51(2):502-509.   Published online June 13, 2018
DOI: https://doi.org/10.4143/crt.2018.117
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We tried to evaluate whether there are any specific features in treatment outcomes of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), compared with gefitinib or erlotinib.
Materials and Methods
We analyzed patients treated with first-line afatinib, gefitinib, or erlotinib for advanced EGFR-mutant NSCLC at Samsung Medical Center between 2014 and 2016.
Results
In total, 467 patients received first-line afatinib (n=165), gefitinib (n=230), or erlotinib (n=72). Afatinib was used more often in patients with tumors harboring deletion in exon 19 (Del19), whereas the gefitinib group had more elderly, females, and never smokers. The median progression-free survival (PFS) time for afatinib, gefitinib, and erlotinib was 19.1 months, 13.7 months, and 14.0 months, respectively (p=0.001). The superior PFS of afatinib was more remarkable in subgroups of Del19 or uncommon EGFR mutations. Overall toxicity profiles of the three drugs were comparable, though more grade 3 or 4 toxicities were detected in afatinib (7.3%) compared with gefitinib (2.6%) or erlotinib (1.8%). The common grade 3 or 4 toxicities of afatinib included diarrhea (3.0%), paronychia (2.4%), and skin rash (1.8%). Dose modification was more frequently required in patients treated with afatinib (112/165, 68%), compared with gefitinib (5/230, 2%) and erlotinib (4/72, 6%). Interestingly, however, dose reduction in the afatinib group did not impair its efficacy in terms of PFS (dose reduction vs. no reduction group, 23.5 months vs. 12.4 months).
Conclusion
First-line afatinib showed satisfactory efficacy data and manageable toxicity profiles.

Citations

Citations to this article as recorded by  
  • Discovery of novel dual tubulin and MMPs inhibitors for the treatment of lung cancer and overcoming drug resistance
    Guimei Li, Meng Wang, Li Luo, Demin Tang, Nan Xu, Rizhen Huang, Yong Yang, Guiping Chen, Zhikun Liu, Hengshan Wang, Xiaochao Huang
    European Journal of Medicinal Chemistry.2025; 285: 117249.     CrossRef
  • Novel bioactive 2‐phenyl‐4‐aminopyrimidine derivatives as EGFRDel19/T790M/C797S inhibitors for the treatment of non‐small cell lung cancer
    Shidi Xu, Zhihui Zhou, Jie He, Jiaojiao Guo, Xiaoling Huang, Yufeng An, Qingshan Pan, Shan Xu, Wufu Zhu
    Archiv der Pharmazie.2024;[Epub]     CrossRef
  • Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
    Tae-Hwan Kim, Jin-Hyuk Choi, Mi Sun Ahn, Hyun Woo Lee, Seok Yun Kang, Yong Won Choi, Young Wha Koh, Seung-Soo Sheen
    BMC Cancer.2024;[Epub]     CrossRef
  • A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
    Cam Phuong Pham, Thi Thai Hoa Nguyen, Anh Tu Do, Tuan Khoi Nguyen, Thi Anh Thu Hoang, Tuan Anh Le, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Van Luan Pham, Minh Hai Nguyen, Thi Huyen Trang Vo, Hung Kien Do, Ha Thanh Vu, Thi
    BMC Cancer.2024;[Epub]     CrossRef
  • Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review
    Maxime Borgeaud, Kaushal Parikh, Giuseppe Luigi Banna, Floryane Kim, Timothée Olivier, Xiuning Le, Alfredo Addeo
    Journal of Thoracic Oncology.2024; 19(7): 973.     CrossRef
  • Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam
    Van Luan Pham, Tuan Anh Le, Cam Phuong Pham, Thi Thai Hoa Nguyen, Anh Tu Do, Tuan Khoi Nguyen, Minh Hai Nguyen, Thi Anh Thu Hoang, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Thi Huyen Trang Vo, Hung Kien Do, Ha Thanh Vu, Thi
    Therapeutic Advances in Medical Oncology.2024;[Epub]     CrossRef
  • Harnessing molecular hybridization approach to discover novel quinoline EGFR-TK inhibitors for cancer treatment
    Noha Ryad, Ayman Abo Elmaaty, Ibrahim M Ibrahim, Ali Hassan Ahmed Maghrabi, Maryam Abdulrahman Yahya Alahdal, Rasha Mohammed Saleem, Islam Zaki, Lina M A Abdel Ghany
    Future Medicinal Chemistry.2024; 16(11): 1087.     CrossRef
  • Lung cancer and pregnancy
    A. L. Chernyshova, A. A. Chernyakov, Ju. M. Trushjuk, O. S. Dil, A. E. Chernyshova
    PULMONOLOGIYA.2024; 34(4): 544.     CrossRef
  • Cytotoxicity and inhibitory potential of CUDC-101 in non-small cell lung cancer cells with rare EGFR L861Q mutation
    Chunhong Chu, Huixia Xu, Chenxue Liu, Xiangkai Wei, Lanxin Li, Rui Wang, Wenrui Cui, Guoliang Zhang, Chenyang Liu, Ke Wang, Lei An, Fei He
    Current Research in Toxicology.2024; 7: 100194.     CrossRef
  • Design and synthesis of novel 2-(2-(4-bromophenyl)quinolin-4-yl)-1,3,4-oxadiazole derivatives as anticancer and antimicrobial candidates: in vitro and in silico studies
    Noha Ryad, Ayman Abo Elmaaty, Samy Selim, Mohammed S. Almuhayawi, Soad K. Al Jaouni, Mohamed S. Abdel-Aziz, Arwa Sultan Alqahtani, Islam Zaki, Lina M. A. Abdel Ghany
    RSC Advances.2024; 14(46): 34005.     CrossRef
  • Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea
    Cliff Molife, Jae Min Cho, Jennifer Lapthorn, Min Ju Kang, Yulia D’yachkova, Sangmi Kim, Sam Colman, Saerom Kim, Agota Szende, Ji Hyun Park, Hee Kyung Ahn, Min Hee Hong, Kaisa-Leena Taipale, Hye Ryun Kim
    Drugs - Real World Outcomes.2023; 10(1): 131.     CrossRef
  • Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer
    Pamela Soberanis Pina, Luis Lara-Mejía, Venecia Matias-Cruz, Feliciano Barrón, Andrés F. Cardona, Luis E. Raez, Eduardo Rios-Garcia, Oscar Arrieta
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
    Gian Marco Leone, Saverio Candido, Alessandro Lavoro, Silvia Vivarelli, Giuseppe Gattuso, Daniela Calina, Massimo Libra, Luca Falzone
    Pharmaceutics.2023; 15(4): 1252.     CrossRef
  • Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
    Vineeth Tatineni, Patrick J. O’Shea, Shreya Saxena, Atulya A. Khosla, Ahmad Ozair, Rupesh R. Kotecha, Xuefei Jia, Yasmeen Rauf, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet S. Ahluwalia
    Cancers.2023; 15(11): 3015.     CrossRef
  • Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma
    Daniela Cárdenas-Fernández, Pamela Soberanis Pina, Jenny G. Turcott, Norberto Chávez-Tapia, Emilio Conde-Flores, Andrés F. Cardona, Oscar Arrieta
    Therapeutic Advances in Medical Oncology.2023;[Epub]     CrossRef
  • Design and Synthesis of Novel Pyrazolopyrimidine Candidates As Promising EGFR-T790M Inhibitors and Apoptosis Inducers
    Ahmed A Gaber, Marwa Sharaky, Ayman Abo Elmaaty, Mohamed M Hammouda, Ahmed AE Mourad, Samy Y Elkhawaga, Mahmoud Mohamed Mokhtar, Amr S Abouzied, Mai AE Mourad, Ahmed A Al-Karmalawy
    Future Medicinal Chemistry.2023; 15(19): 1773.     CrossRef
  • Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs
    Huang‐Chih Chang, Chin‐Chou Wang, Chia‐Cheng Tseng, Kuo‐Tung Huang, Yu‐Mu Chen, Yu‐Ping Chang, Chien‐Hao Lai, Wen‐Feng Fang, Meng‐Chih Lin, Hung‐Yi Chuang
    Thoracic Cancer.2023; 14(32): 3208.     CrossRef
  • Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of real‐world evidence
    Huang‐Chih Chang, Kuo‐Tung Huang, Chia‐Cheng Tseng, Yu‐Mu Chen, Chien‐Hao Lai, Yu‐Ping Chang, Yung‐Che Chen, Hung‐Yi Chuang, Chin‐Chou Wang
    Thoracic Cancer.2023; 14(32): 3217.     CrossRef
  • Pyrrolo[2,1-f][1,2,4]triazine: a promising fused heterocycle to target kinases in cancer therapy
    Sarbjit Singh, Divya Utreja, Vimal Kumar
    Medicinal Chemistry Research.2022; 31(1): 1.     CrossRef
  • The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
    Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang
    Cancer Research and Treatment.2022; 54(2): 434.     CrossRef
  • Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
    Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Kuo, Ping-Chih Hsu, John Chang
    Cancers.2022; 14(3): 674.     CrossRef
  • Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
    John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
    Cancers.2022; 14(4): 977.     CrossRef
  • Two Unusual Mutations in the Epidermal Growth Factor Receptor Gene in a Patient With Lung Adenocarcinoma
    Martin Zapata Laguado, Andrea Zuluaga, Rafael Parra Medina, Ricardo Bruges
    Cureus.2022;[Epub]     CrossRef
  • Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands
    Hong-Yi Zhao, Hai-Peng Wang, Yu-Ze Mao, Hao Zhang, Minhang Xin, Xiao-Xiao Xi, Hao Lei, Shuai Mao, Dong-Hui Li, San-Qi Zhang
    Journal of Medicinal Chemistry.2022; 65(6): 4709.     CrossRef
  • Cost-Effectiveness Analysis of Afatinib versus Gefitinib in Non-small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Mutation in Indonesia: Observational studies with Retrospectives
    Seftika Sari, Tri Murti Andayani, Dwi Endarti, Kartika Widayati
    Research Journal of Pharmacy and Technology.2022; : 1598.     CrossRef
  • Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
    Rong Liu, Jianying Zhou, Xia Ling
    Clinical Medicine Insights: Oncology.2022;[Epub]     CrossRef
  • Pharmacokinetic and Safety Comparison of 2 Afatinib Dimaleate Tablets in Healthy Chinese Volunteers Under Fasted Conditions: A Randomized, Open‐Label, 2‐Period, Single‐Dose Crossover Study
    Ping Shi, Xin Jiang, Ye Tao, Ting Li, Xin Li, Chenjing Wang, Yanping Liu, Yaping Ma, Xiaomeng Gao, Yu Cao
    Clinical Pharmacology in Drug Development.2022; 11(10): 1177.     CrossRef
  • Grb2 interacts with necrosome components and is involved in rasfonin-induced necroptosis
    Bolin Hou, Haiwen Huang, Yueqian Li, Jingnan Liang, Zhijun Xi, Xuejun Jiang, Ling Liu, Erwei Li
    Cell Death Discovery.2022;[Epub]     CrossRef
  • Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs
    Hong-Yi Zhao, Xiao-Xiao Xi, Minhang Xin, San-Qi Zhang
    Bioorganic Chemistry.2022; 128: 106057.     CrossRef
  • Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity
    Amr Sonousi, Rasha A. Hassan, Eman O. Osman, Amr M. Abdou, Soha H. Emam
    Journal of Enzyme Inhibition and Medicinal Chemistry.2022; 37(1): 2644.     CrossRef
  • Analysis of non-small cell lung cancer with miliary lung metastasis in patients harboring epidermal growth factor receptor mutations
    Ming-Hung Chang, Kuo-Hwa Chiang, Jiunn-Min Shieh, Kuo-Chen Cheng, Chung-Han Ho
    Scientific Reports.2022;[Epub]     CrossRef
  • Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations
    Kartik Sehgal, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, Daniel B. Costa
    The Oncologist.2021; 26(4): 281.     CrossRef
  • Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
    Cheol‐Kyu Park, Sung‐Yong Lee, Jae Cheol Lee, Chang‐Min Choi, Shin Yup Lee, Tae‐Won Jang, In‐Jae Oh, Young‐Chul Kim
    Thoracic Cancer.2021; 12(4): 444.     CrossRef
  • Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells
    Boonyakorn Boonsri, Kiren Yacqub-Usman, Pakpoom Thintharua, Kyaw Zwar Myint, Thannicha Sae-Lao, Pam Collier, Chinnawut Suriyonplengsaeng, Noppadol Larbcharoensub, Brinda Balasubramanian, Simran Venkatraman, Isioma U. Egbuniwe, Dhanwant Gomez, Abhik Mukher
    Cancer Research and Treatment.2021; 53(2): 457.     CrossRef
  • Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
    Sheng-Kai Liang, Li-Ta Keng, Chia-Hao Chang, Yueh-Feng Wen, Meng-Rui Lee, Ching-Yao Yang, Jann-Yuan Wang, Jen-Chung Ko, Jin-Yuan Shih, Chong-Jen Yu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
    Sojung Park, Sung Yong Lee, Dojin Kim, Yun Su Sim, Jeong-Seon Ryu, Juwhan Choi, Su Hwan Lee, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang
    BMC Cancer.2021;[Epub]     CrossRef
  • Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study
    Burak Bilgin, Mehmet Ali Nahit Sendur, Sebnem Yucel, Emir Celik, Deniz Tataroglu Ozyukseler, Murat Ayhan, Tugba Basoglu, Aysegul Ilhan, Nadiye Akdeniz, Ahmet Gulmez, Izzet Dogan, Burak Yasin Aktas, Mustafa Gurbuz, Sinan Koca, Semra Paydas, Ali Murat Tatli
    Journal of Cancer Research and Clinical Oncology.2021; 147(7): 2145.     CrossRef
  • Gefitinib reduces oocyte quality by disturbing meiotic progression
    Hong-Yong Zhang, Ying-Chun Ouyang, Jian Li, Chun-Hui Zhang, Wei Yue, Tie-Gang Meng, Heide Schatten, Qing-Yuan Sun, Wei-Ping Qian
    Toxicology.2021; 452: 152705.     CrossRef
  • Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study
    Kristof Cuppens, Liesbet Lodewyckx, Ingel Demedts, Lore Decoster, Benoît Colinet, Koen Deschepper, Annelies Janssens, Daniella Galdermans, Thierry Pieters
    Drugs - Real World Outcomes.2021; 8(2): 141.     CrossRef
  • Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
    Shun Lu, Jin-Yuan Shih, Tae-Won Jang, Chong-Kin Liam, Yongfeng Yu
    Advances in Therapy.2021; 38(5): 2038.     CrossRef
  • PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment
    Cheng-Yu Chang, Yi-Chun Lai, Yu-Feng Wei, Chung-Yu Chen, Shih-Chieh Chang
    OncoTargets and Therapy.2021; Volume 14: 2301.     CrossRef
  • Egfr Tyrosine Kinase Inhibitors for EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Outcomes in Asian Populations
    Edward S Kim, Barbara Melosky, Keunchil Park, Nobuyuki Yamamoto, James C - H Yang
    Future Oncology.2021; 17(18): 2395.     CrossRef
  • The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
    Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang
    Scientific Reports.2021;[Epub]     CrossRef
  • Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
    Antonio Passaro, Filippo de Marinis, Hai-Yan Tu, Konstantin K. Laktionov, Jifeng Feng, Artem Poltoratskiy, Jun Zhao, Eng Huat Tan, Maya Gottfried, Victor Lee, Dariusz Kowalski, Cheng Ta Yang, BJ Srinivasa, Laura Clementi, Tejaswini Jalikop, Dennis Chin Lu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
    Keunchil Park, Jin-Soo Kim, Joo-Hang Kim, Young-Chul Kim, Hoon-Gu Kim, Eun Kyung Cho, Jong-Youl Jin, Miyoung Kim, Angela Märten, Jin-Hyoung Kang
    BMC Cancer.2021;[Epub]     CrossRef
  • Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea
    Taeyun Kim, Tae Won Jang, Chang Min Choi, Mi‐Hyun Kim, Sung Yong Lee, Cheol‐Kyu Park, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Chan Kwon Park, Sang Hoon Lee, Seung Hun Jang, Seong Hoon Yoon
    Cancer Medicine.2021; 10(17): 5809.     CrossRef
  • Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
    Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, John Wen-Cheng Chang
    BMC Cancer.2021;[Epub]     CrossRef
  • Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
    Po-Yen Chen, Chin-Chou Wang, Chien-Ning Hsu, Chung-Yu Chen
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
    Filippo Papini, Janani Sundaresan, Alessandro Leonetti, Marcello Tiseo, Christian Rolfo, Godefridus J. Peters, Elisa Giovannetti
    Critical Reviews in Oncology/Hematology.2021; 166: 103454.     CrossRef
  • Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer
    Hayato Yokota, Kazuhiro Sato, Sho Sakamoto, Yuji Okuda, Mariko Asano, Masahide Takeda, Katsutoshi Nakayama, Masatomo Miura
    Biology.2021; 10(10): 1054.     CrossRef
  • Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
    Yamin Shu, Qilin Zhang, Xucheng He, Li Chen
    Cancer Management and Research.2021; Volume 13: 8297.     CrossRef
  • Impact of Dose Reduction of Afatinib Used in Patients With Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Ziyu Wang, Xin Du, Ken Chen, Shanshan Li, Zhiheng Yu, Ziyang Wu, Li Yang, Dingding Chen, Wei Liu
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • EFIKASI TERAPI EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKIs) PADA KANKER PARU
    Fitri Wulandari, Widyaningrum Utami, Evieta Rohana, Wimzy Rizqy Prabhata
    Generics: Journal of Research in Pharmacy.2021;[Epub]     CrossRef
  • Comparing the effectiveness of different EGFR‐TKIs in patients with EGFR mutant non–small‐cell lung cancer: A retrospective cohort study in Taiwan
    Yao‐Yu Hsieh, Wei‐Tse Fang, Yu‐Wen Lo, Yi‐Han Chen, Li‐Nien Chien
    International Journal of Cancer.2020; 147(4): 1107.     CrossRef
  • Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
    James Chih-Hsin Yang, Martin Schuler, Sanjay Popat, Satoru Miura, Simon Heeke, Keunchil Park, Angela Märten, Edward S. Kim
    Journal of Thoracic Oncology.2020; 15(5): 803.     CrossRef
  • Anticancer activity evaluation of indazolyl-substituted piperidin-4-yl-aminopyrimidines
    Chao Wang, Xiao-Wen Liu, Ting Xiao, Zhi-Qiang Xu, Shuang Cao, Hai-Feng Wang, Qiong-Jiao Yan, Shuang-Xi Gu, Yuan-Yuan Zhu
    Medicinal Chemistry Research.2020; 29(5): 910.     CrossRef
  • Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer
    Xiao-yun Liu, Zi-tao Guo, Zhen-dong Chen, Yi-fan Zhang, Jia-lan Zhou, Yong Jiang, Qian-yu Zhao, Xing-xing Diao, Da-fang Zhong
    Acta Pharmacologica Sinica.2020; 41(10): 1366.     CrossRef
  • Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives
    Giulia Sartori, Lorenzo Belluomini, Fiorella Lombardo, Alice Avancini, Ilaria Trestini, Emanuele Vita, Daniela Tregnago, Jessica Menis, Emilio Bria, Michele Milella, Sara Pilotto
    Expert Review of Anticancer Therapy.2020; 20(7): 531.     CrossRef
  • Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study
    Ye Jiang, Wenli Chen, Weiguang Yu, Ning Shi, Guowei Han, Shuai Mao, Xinlei Zhang, Meiji Chen
    Journal of International Medical Research.2020;[Epub]     CrossRef
  • Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry
    Kristian Brat, Monika Bratova, Jana Skrickova, Magda Barinova, Karolina Hurdalkova, Milos Pesek, Libor Havel, Leona Koubkova, Michal Hrnciarik, Jana Krejci, Ondrej Fischer, Milada Zemanova, Helena Coupkova, Martin Svaton
    Thoracic Cancer.2020; 11(11): 3346.     CrossRef
  • Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
    Shouzheng Wang, Puyuan Xing, Ke Yang, Xuezhi Hao, Di Ma, Yuxin Mu, Junling Li
    Thoracic Cancer.2019; 10(6): 1461.     CrossRef
  • Afatinib/gefitinib

    Reactions Weekly.2019; 1753(1): 17.     CrossRef
  • Current Approaches in NSCLC Targeting K-RAS and EGFR
    Veronica Aran, Jasminka Omerovic
    International Journal of Molecular Sciences.2019; 20(22): 5701.     CrossRef
  • Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA
    Jonathan Lim, Carl Samuelsen, Amanda Golembesky, Sulena Shrestha, Li Wang, Ingolf Griebsch
    Future Oncology.2019; 15(13): 1493.     CrossRef
  • Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
    Maximilian J Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten, Tanja Cufer
    Future Oncology.2018; 14(27): 2861.     CrossRef
  • 13,102 View
  • 812 Download
  • 76 Web of Science
  • 65 Crossref
Close layer
Case Report
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
Jiyun Lee, Joon Ho Shim, Woong-Yang Park, Hee Kyung Kim, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(1):408-412.   Published online May 23, 2018
DOI: https://doi.org/10.4143/crt.2018.138
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Epidermal growth factor receptor (EGFR)‒tyrosine kinase inhibitors (TKIs) are effective clinical therapeutics for EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib, a thirdgeneration EGFR TKI, has proven effective against T790M mutations. However, the vast majority of patients acquire resistance following successful treatment. A 59-year-old female patient with metastatic NSCLC developed resistance after 43 weeks of osimertinib. CancerSCAN of the metastatic liver lesion revealed a EGFR C797G mutation at an allele frequency of 72%, a preexisting T790M mutation (73%) in cis and an exon 19 deletion (87%). Another 53-year-old female patient developed systemic progression after 10 months of osimertinib. CancerSCAN of the lung biopsy identified an EGFR L718Q mutation at an allele frequency of 7%, concomitant PIK3CA E545K (12.90%) and preexisting EGFR L858R (38%), but loss of the T790M mutation. The heterogeneity of osimertinib resistance mechanisms warrants further investigation into novel or combination agents to overcome the rare acquired resistances.

Citations

Citations to this article as recorded by  
  • Comparative analysis of batch correction methods for FDG PET/CT using metabolic radiogenomic data of lung cancer patients
    Hyunjong Lee, Sujin Seo, Sungho Won, Woong-Yang Park, Joon Young Choi, Kyung-Han Lee, Se-Hoon Lee, Seung Hwan Moon
    Scientific Reports.2023;[Epub]     CrossRef
  • Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer
    Xueli Tian, Tingxuan Gu, Mee-Hyun Lee, Zigang Dong
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2022; 1877(1): 188645.     CrossRef
  • Overview of the multifaceted resistances toward EGFR-TKIs and new chemotherapeutic strategies in non-small cell lung cancer
    Rashidi Dzul Keflee, Kok Hoong Leong, Satoshi Ogawa, Jerome Bignon, Mun Chiang Chan, Kin Weng Kong
    Biochemical Pharmacology.2022; 205: 115262.     CrossRef
  • Novel Resistance Mechanisms to Osimertinib Analysed by Whole-Exome Sequencing in Non-Small Cell Lung Cancer
    Zhen Wu, Wei Zhao, Zhen Yang, Yue Ming Wang, Yu Dai, Liang-An Chen
    Cancer Management and Research.2021; Volume 13: 2025.     CrossRef
  • Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment
    Hong-Shuai Li, Guang-Jian Yang, Yan Wang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy
    Balázs Jóri, Stefanie Schatz, Len Kaller, Bettina Kah, Julia Roeper, Hayat O. Ramdani, Linda Diehl, Petra Hoffknecht, Christian Grohé, Frank Griesinger, Markus Tiemann, Lukas C. Heukamp, Markus Falk
    Cancers.2021; 13(12): 2861.     CrossRef
  • Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
    Sehhoon Park, Chung Lee, Bo Mi Ku, Minjae Kim, Woong-Yang Park, Nayoung K. D. Kim, Myung-Ju Ahn
    BMB Reports.2021; 54(7): 386.     CrossRef
  • Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases
    Janina Niggenaber, Julia Hardick, Jonas Lategahn, Daniel Rauh
    Journal of Medicinal Chemistry.2020; 63(1): 40.     CrossRef
  • Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations
    Gahyun Kim, Jinho Kim, Hongui Cha, Woong-Yang Park, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Yong-Jin Park, Joon Young Choi, Kyung-Han Lee, Se-Hoon Lee, Seung Hwan Moon
    Scientific Reports.2020;[Epub]     CrossRef
  • Afatinib/gefitinib/osimertinib

    Reactions Weekly.2019; 1741(1): 16.     CrossRef
  • Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
    Jing Liu, Bo Jin, Hang Su, Xiujuan Qu, Yunpeng Liu
    BMC Cancer.2019;[Epub]     CrossRef
  • Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
    Rashmi R. Shah, Devron R. Shah
    Drug Safety.2019; 42(2): 181.     CrossRef
  • A novel PI3K/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC
    Yuanhao Lv, Tingting Du, Ming Ji, Chunyang Wang, Songwen Lin, Nina Xue, Jing Jin, Heng Xu, Xiaoguang Chen
    Journal of Drug Targeting.2018; : 1.     CrossRef
  • 9,795 View
  • 459 Download
  • 13 Web of Science
  • 13 Crossref
Close layer
Original Articles
Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer
Jong Ho Cho, Wei Zhou, Yoon-La Choi, Jong-Mu Sun, Hyejoo Choi, Tae-Eun Kim, Marisa Dolled-Filhart, Kenneth Emancipator, Mary Anne Rutkowski, Jhingook Kim
Cancer Res Treat. 2018;50(1):95-102.   Published online March 17, 2017
DOI: https://doi.org/10.4143/crt.2016.591
AbstractAbstract PDFPubReaderePub
Purpose
Data are limited on programmed death ligand 1 (PD-L1) expression in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC).
Materials and Methods
We retrospectively evaluated the relationship between PD-L1 expression and recurrence-free survival (RFS) and overall survival in 319 patients with EGFR-mutant NSCLC who were treated at Samsung Medical Center from 2006 to 2014. Membranous PD-L1 expression on tumor cells was measured using the PD-L1 IHC 22C3 pharmDx antibody and reported as tumor proportion score (TPS). Kaplan-Meier methods, log-rank test, and Cox proportional hazards models were used for survival analysis.
Results
All patients had ≥ 1 EGFR mutation—54% in exon 19 and 39% in exon 21. Overall, 51% of patients had PD-L1–positive tumors. The prevalence of PD-L1 positivity was higher among patients with stages II-IV versus stage I disease (64% vs. 44%) and among patients with other EGFR mutations (75%) than with L858R mutation (39%) or exon 19 deletion (52%). PD-L1 positivity was associated with shorter RFS, with an adjusted hazard ratio of 1.52 (95% confidence interval [CI], 0.81 to 2.84; median, 18 months) for the PD-L1 TPS ≥ 50% group, 1.51 (95% CI, 1.02 to 2.21; median, 31 months) for the PD-L1 TPS 1%-49% group, and 1.51 (95% CI, 1.05 to 2.18) for the combined PD-L1–positive groups (TPS ≥ 1%) compared with the PD-L1–negative group (median, 35 months).
Conclusion
PD-L1 expression is associated with disease stage and type of EGFR mutation. PD-L1 positivity might be associated with worse RFS among patients with surgically treated EGFR-mutant NSCLC.

Citations

Citations to this article as recorded by  
  • Spatial Heterogeneity of PD‐L1 Expression as a Biomarker for Third‐Generation EGFR‐TKI Response in Advanced EGFR‐Mutant NSCLC
    Yidan Zhang, Yingqi Xu, Hongping Jin, Tengfei Liu, Hua Zhong, Jianlin Xu, Yuqing Lou, Runbo Zhong
    Cancer Science.2025; 116(6): 1648.     CrossRef
  • The role of PD-L1 in EGFR-mutant non-small cell lung cancer
    Wentao Gao, Lingling Wang, Yanyan Zhao, Lucheng Zhu
    Discover Oncology.2025;[Epub]     CrossRef
  • Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review
    Yi Dong, Liaqat Khan, Yi Yao
    Journal of the National Cancer Center.2024; 4(4): 289.     CrossRef
  • Activatable near-infrared fluorescence probe for real-time imaging of PD-L1 expression in tumors
    Hyunjin Kim, Maixian Liu, Chan Hyeok Park, Byung Il Lee, Hyonchol Jang, Yongdoo Choi
    Journal of Materials Chemistry B.2024; 12(42): 10877.     CrossRef
  • Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer
    Si‐Yu Lei, Hai‐Yan Xu, Hong‐Shuai Li, Ya‐Ning Yang, Fei Xu, Jun‐Ling Li, Zhi‐Jie Wang, Pu‐Yuan Xing, Xue‐Zhi Hao, Yan Wang
    Thoracic Cancer.2023; 14(24): 2327.     CrossRef
  • Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR‐mutated NSCLC
    Yusuke Hamakawa, Yoko Agemi, Aya Shiba, Toshiki Ikeda, Yuko Higashi, Masaharu Aga, Kazuhito Miyazaki, Yuri Taniguchi, Yuki Misumi, Yukiko Nakamura, Tsuneo Shimokawa, Yusuke Saigusa, Nobuaki Kobayashi, Hiroaki Okamoto, Takeshi Kaneko
    Cancer Medicine.2023; 12(17): 17788.     CrossRef
  • Determining Risk Factors Associated with Depression and Anxiety in Young Lung Cancer Patients: A Novel Optimization Algorithm
    Yu-Wei Fang, Chieh-Yu Liu
    Medicina.2021; 57(4): 340.     CrossRef
  • Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
    Edouard Dantoing, Nicolas Piton, Mathieu Salaün, Luc Thiberville, Florian Guisier
    International Journal of Molecular Sciences.2021; 22(12): 6288.     CrossRef
  • Programmed Death Ligand 1 Expression and Related Markers in Pleuropulmonary Blastoma
    Zahra Alipour, Kris Ann P Schultz, Ling Chen, Anne K Harris, Ivan A Gonzalez, John Pfeifer, D Ashley Hill, Mai He, Louis P Dehner
    Pediatric and Developmental Pathology.2021; 24(6): 523.     CrossRef
  • The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC
    Bo Lan, Yongfang Wang, Jingni Wu, Kai Wang, Pingli Wang
    Medicine.2021; 100(34): e27038.     CrossRef
  • The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay
    Matthew Evans, Brendan O’Sullivan, Frances Hughes, Tina Mullis, Matthew Smith, Nicola Trim, Philippe Taniere
    Pathology & Oncology Research.2020; 26(1): 79.     CrossRef
  • PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer
    Eriko Miyawaki, Haruyasu Murakami, Keita Mori, Nobuaki Mamesaya, Takahisa Kawamura, Haruki Kobayashi, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Toshiaki Takahashi
    Japanese Journal of Clinical Oncology.2020; 50(5): 617.     CrossRef
  • Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma
    Mai He, Brooj Abro, Madhurima Kaushal, Ling Chen, Tiffany Chen, Mercia Gondim, Weisi Yan, Julie Neidich, Louis P. Dehner, John D. Pfeifer
    Human Pathology.2020; 100: 15.     CrossRef
  • Clinicopathological characteristics of primary lung nuclear protein in testis carcinoma: A single‐institute experience of 10 cases
    Yoon Ah Cho, Yoon‐La Choi, Inwoo Hwang, Kyungjong Lee, Jong Ho Cho, Joungho Han
    Thoracic Cancer.2020; 11(11): 3205.     CrossRef
  • Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma
    Jang Ho Cho, Hyun Ae Jung, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jong-Mu Sun
    Journal of Cancer Research and Clinical Oncology.2019; 145(5): 1341.     CrossRef
  • The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer
    Yang Zhang, Yuanyuan Zeng, Ting Liu, Wenwen Du, Jianjie Zhu, Zeyi Liu, Jian-an Huang
    Respiratory Research.2019;[Epub]     CrossRef
  • Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
    Lee, Kim, Sung, Lee, Han, Kim, Choi
    International Journal of Molecular Sciences.2019; 20(19): 4794.     CrossRef
  • Clinical and Molecular Predictors of PD-L1 Expression in Non–Small-Cell Lung Cancer: Systematic Review and Meta-analysis
    Fausto Petrelli, Mariangela Maltese, Gianluca Tomasello, Barbara Conti, Karen Borgonovo, Mary Cabiddu, Mara Ghilardi, Michele Ghidini, Rodolfo Passalacqua, Sandro Barni, Matteo Brighenti
    Clinical Lung Cancer.2018; 19(4): 315.     CrossRef
  • Status of programmed death-ligand 1 expression in sarcomas
    Hyung Kyu Park, Mingi Kim, Minjung Sung, Seung Eun Lee, Yu Jin Kim, Yoon-La Choi
    Journal of Translational Medicine.2018;[Epub]     CrossRef
  • Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis
    Bo Lan, Chengxi Ma, Chengyan Zhang, Shoujie Chai, Pingli Wang, Liren Ding, Kai Wang
    Oncotarget.2018; 9(7): 7684.     CrossRef
  • Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma
    Byung Soo Lee, Dong Il Park, Da Hye Lee, Jeong Eun Lee, Min-kyung Yeo, Yeon Hee Park, Dae Sik Lim, Wonyoung Choi, Da Hye Lee, Geon Yoo, Han-byul Kim, Dahyun Kang, Jae Young Moon, Sung Soo Jung, Ju Ock Kim, Sang Yeon Cho, Hee Sun Park, Chaeuk Chung
    Biochemical and Biophysical Research Communications.2017; 491(2): 493.     CrossRef
  • 13,386 View
  • 653 Download
  • 25 Web of Science
  • 21 Crossref
Close layer
Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer
Min-Young Lee, Bo Mi Ku, Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Jong-Mu Sun, Se-Hoon Lee, Keunchil Park, Young Lyun Oh, Mineui Hong, Han-Sin Jeong, Young-Ik Son, Chung-Hwan Baek, Myung-Ju Ahn
Cancer Res Treat. 2017;49(4):906-914.   Published online December 26, 2016
DOI: https://doi.org/10.4143/crt.2016.424
AbstractAbstract PDFPubReaderePub
Purpose
Papillary thyroid carcinomas (PTCs) frequently involve genetic alterations. The objective of this study was to investigate genetic alterations and further explore the relationships between these genetic alterations and clinicopathological characteristics in a high-recurrence risk (node positive, N1) PTC group.
Materials and Methods
Tumor tissue blocks were obtained from 240 surgically resected patients with histologically confirmed stage III/IV (pT3/4 or N1) PTCs. We screened gene fusions using NanoString’s nCountertechnology and mutational analysiswas performed by directDNA sequencing.Data describing the clinicopathological characteristics and clinical courses were retrospectively collected.
Results
Of the 240 PTC patients, 207 (86.3%) had at least one genetic alteration, including BRAF mutation in 190 patients (79.2%), PIK3CA mutation in 25 patients (10.4%), NTRK1/3 fusion in six patients (2.5%), and RET fusion in 24 patients (10.0%). Concomitant presence of more than two genetic alterations was seen in 36 patients (15%). PTCs harboring BRAF mutation were associated with RET wild-type expression (p=0.001). RET fusion genes have been found to occur with significantly higher frequency in N1b stage patients (p=0.003) or groups of patients aged 45 years or older (p=0.031); however, no significant correlation was found between other genetic alterations. There was no trend toward favorable recurrence-free survival or overall survival among patients lacking genetic alterations.
Conclusion
In the selected high-recurrence risk PTC group, most patients had more than one genetic alteration. However, these known alterations could not entirely account for clinicopathological features of high-recurrence risk PTC.

Citations

Citations to this article as recorded by  
  • Role of contrast-enhanced ultrasound with time-intensity curve analysis about thyroid nodule and parenchyma for differentiating BRAF V600E mutation status
    Zhipeng Hu, Rong Xue, Zhixi Liu, Liang Liu, Zheli Gong
    PeerJ.2025; 13: e19006.     CrossRef
  • BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma
    Nobuyuki Bandoh, Takashi Goto, Yasutaka Kato, Akinobu Kubota, Shota Sakaue, Ryuhei Takeda, Shuto Hayashi, Misaki Hayashi, Shogo Baba, Tomomi Yamaguchi-Isochi, Hiroshi Nishihara, Hajime Kamada
    Asian Journal of Surgery.2024; 47(1): 413.     CrossRef
  • FHL1: A novel diagnostic marker for papillary thyroid carcinoma
    Yeting Zeng, Dehua Zeng, Xingfeng Qi, Hanxi Wang, Xuzhou Wang, Xiaodong Dai, Lijuan Qu
    Pathology International.2024; 74(9): 520.     CrossRef
  • Rearranged During Transfection Rearrangement Detection by Fluorescence In Situ Hybridization Compared With Other Techniques in NSCLC
    Anne Mc Leer, Julie Mondet, Nelly Magnat, Mailys Mersch, Diane Giovannini, Camille Emprou, Anne-Claire Toffart, Nathalie Sturm, Sylvie Lantuéjoul, David Benito
    JTO Clinical and Research Reports.2024; 5(12): 100714.     CrossRef
  • Essential news for clinical practice—thyroid cancer
    Barbara Kiesewetter, Ladislaia Wolff, Markus Raderer
    memo - Magazine of European Medical Oncology.2023; 16(1): 47.     CrossRef
  • A new paradigm for epidermal growth factor receptor expression exists in PTC and NIFTP regulated by microRNAs
    Abeer Al-Abdallah, Iman Jahanbani, Rola H. Ali, Nabeel Al-Brahim, Jeena Prasanth, Bashayer Al-Shammary, Maie Al-Bader
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • NanoString in the screening of genetic abnormalities associated with thyroid cancer
    Elisabetta Macerola, Anello Marcello Poma, Fulvio Basolo
    Seminars in Cancer Biology.2022; 79: 132.     CrossRef
  • The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations
    Steve Duff, Francesca Bargiacchi, Chelsea Norregaard, Melanie Brener, Erin Sullivan
    Journal of Managed Care & Specialty Pharmacy.2022; 28(2): 218.     CrossRef
  • Thyroid cancer incidence disparities among ethnic Asian American populations, 1990–2014
    Alice W. Lee, Roy A. Mendoza, Shehla Aman, Robert Hsu, Lihua Liu
    Annals of Epidemiology.2022; 66: 28.     CrossRef
  • Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization
    Jessica A. Baker, Anthony N. Sireci, Narasimha Marella, Holly Kay Cannon, Tyler J. Marquart, Timothy R. Holzer, Leslie O'Neill Reising, Joel D. Cook, Sameera R. Wijayawardana, Juraj Bodo, Eric D. Hsi, Andrew E. Schade, Gerard J. Oakley
    Archives of Pathology & Laboratory Medicine.2022; 146(3): 351.     CrossRef
  • Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance
    Laura Fugazzola, Marina Muzza, Gabriele Pogliaghi, Mario Vitale
    Cancers.2020; 12(2): 383.     CrossRef
  • The stress-activated protein kinase pathway and the expression of stanniocalcin-1 are regulated by miR-146b-5p in papillary thyroid carcinogenesis
    Abeer Al-Abdallah, Iman Jahanbani, Heba Mehdawi, Rola H Ali, Nabeel Al-Brahim, Olusegun Mojiminiyi
    Cancer Biology & Therapy.2020; 21(5): 412.     CrossRef
  • Risk Stratification Using a Novel Genetic Classifier IncludingPLEKHS1Promoter Mutations for Differentiated Thyroid Cancer with Distant Metastasis
    Chan Kwon Jung, Seung-Hyun Jung, Sora Jeon, Young Mun Jeong, Yourha Kim, Sohee Lee, Ja-Seong Bae, Yeun-Jun Chung
    Thyroid.2020; 30(11): 1589.     CrossRef
  • Prediction of cervical lymph node metastasis with contrast-enhanced ultrasound and association between presence of BRAFV600E and extrathyroidal extension in papillary thyroid carcinoma
    Jia Zhan, Long-hui Zhang, Qing Yu, Chao-lun Li, Yue Chen, Wen-Ping Wang, Hong Ding
    Therapeutic Advances in Medical Oncology.2020;[Epub]     CrossRef
  • Clinical significance of eukaryotic translation initiation factor 5A2 in papillary thyroid cancer
    Hongmei Zhang, Kejun Zhang, Liang Ning, Dong Chen, Fengyun Hao, Peng Li
    Bioengineered.2020; 11(1): 1325.     CrossRef
  • High Preponderance of BRAF V600E Mutation in Papillary Thyroid Carcinoma Among Filipinos: A Clinicopathologic Study
    Gerard Anthony M. Espiritu, Joemari T. Malana, Arlie Jean Grace V. Dumasis, Daphne C. Ang
    Journal of Global Oncology.2019; (5): 1.     CrossRef
  • PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis
    Ali Alqahtani, Hazem S. K. Ayesh, Hafez Halawani
    Cancers.2019; 12(1): 93.     CrossRef
  • Targeted next‑generation sequencing of cancer‑related genes in thyroid carcinoma: A single institution's experience
    Nobuyuki Bandoh, Toshiaki Akahane, Takashi Goto, Michihisa Kono, Haruyuki Ichikawa, Takahiro Sawada, Tomomi Yamaguchi, Hiroshi Nakano, Yumiko Kawase, Yasutaka Kato, Hajime Kamada, Yasuaki Harabuchi, Kazuo Shimizu, Hiroshi Nishihara
    Oncology Letters.2018;[Epub]     CrossRef
  • Niclosamide induces apoptosis through mitochondrial intrinsic pathway and inhibits migration and invasion in human thyroid cancer in vitro
    Kai Yu, Tingting Wang, Yujue Li, Chun Wang, Xia Wang, Mei Zhang, Yongmei Xie, Shuangqing Li, Zhenmei An, Tinghong Ye
    Biomedicine & Pharmacotherapy.2017; 92: 403.     CrossRef
  • 11,535 View
  • 371 Download
  • 21 Web of Science
  • 19 Crossref
Close layer
Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience
Hyojung Park, Dongryul Oh, Yong Chan Ahn, Hongryull Pyo, Jae Myung Noh, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Jae Ill Zo, Young Mog Shim
Cancer Res Treat. 2017;49(4):880-889.   Published online December 12, 2016
DOI: https://doi.org/10.4143/crt.2016.442
AbstractAbstract PDFPubReaderePub
Purpose
The optimal adjuvant therapy modality for treating pN2 non-small cell lung cancer patients has not yet been established. In this study, the authors investigated clinical outcomes following three different adjuvant therapy modalities.
Materials and Methods
From January 2006 to December 2012, 240 patients with cN0/1 disease were found to have pN2 disease following curative resection and received one of three adjuvant therapy modalities:thoracic radiation therapy (TRT) and concurrent chemotherapy (CTx) (CCRT) (group I), CCRT plus consolidation CTx (group II), and CTx alone (group III). TRT was delivered to 155 patients (groups I/II), and full dose CTxwas delivered to 172 patients either as a consolidative or a sole modality (group II/III).
Results
During 30 months of median follow-up, 44 patients died and 141 developed recurrence. The 5-year overall survival (OS), locoregional control (LRC), distant metastasis-free survival (DMFS), and disease-free survival (DFS) rates of all patients were 76.2%, 80.7%, 36.4%, and 29.6%, respectively. There was no difference in OS among groups. TRT (groups I/II) significantly improved LRC, full dose CTx (groups II/III) did DMFS, and CCRT plus consolidation CTx (group II) did DFS, respectively.
Conclusion
The current study could support that TRT could improve LRC and full dose CTx could improve DMFS and that CCRT plus consolidation CTx could improve DFS.

Citations

Citations to this article as recorded by  
  • The effect of adjuvant chemoradiotherapy on survival after R0 resection for stage III-N2 nonsmall cell lung cancer: A meta-analysis
    Dailong Li, Wanqiang Li, Yaqi Pang, Lu Xu, Xinhua Xu
    Medicine.2022; 101(28): e29580.     CrossRef
  • The efficacy of postoperative radiotherapy for patients with non-small cell lung cancer
    Zexu Wang, Baixia Yang, Ping Zhan, Li Wang, Bing Wan
    Journal of Cancer Research and Therapeutics.2022; 18(7): 1910.     CrossRef
  • 44,516 View
  • 260 Download
  • 3 Web of Science
  • 2 Crossref
Close layer
A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma
Sung Hee Lim, Young Mog Shim, Se Hoon Park, Hong Kwan Kim, Young Soo Choi, Myung-Ju Ahn, Keunchil Park, Jae Ill Zo, Jong-Mu Sun
Cancer Res Treat. 2017;49(3):816-823.   Published online November 9, 2016
DOI: https://doi.org/10.4143/crt.2016.417
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The optimal perioperative treatment for resectable esophageal squamous cell carcinoma (ESCC) remains controversial. We evaluated the efficacy and safety of leucovorin and 5-fluorouracil (LV5FU2) and LV5FU2 plus oxaliplatin (FOLFOX) combination chemotherapies administered adjuvantly for curatively-resected, node-positive ESCC.
Materials and Methods
Patients with pathologically node-positive esophageal cancer after curative R0 resection were enrolled and randomly assigned to receive LV5FU2 or FOLFOX biweekly for up to eight cycles. The primary endpoint was disease-free survival (DFS).
Results
Between 2011 and 2015, 62 patients were randomized into the two treatment groups (32 in the LV5FU2 arm and 30 in the FOLFOX arm). The median age was 60 years and both groups had similar pathologic characteristics in tumor, nodal status, and location. Treatment completion rates were similarly high in both groups. The DFS rate at 12 months was 67% in the LV5FU2 group and 63% in the FOLFOX group with a hazard ratio of 1.3 (95% confidence interval [CI], 0.66 to 2.62). After a median follow-up period of 27 months, the median DFS was 29.6 months (95% CI, 4.9 to 54.2) in the LV5FU2 arm and 16.8 months (95% CI, 7.5 to 26.1) in the FOLFOX arm (p=0.428), respectively, while the median overall survival was not reached in either arm. Grade 3 or 4 neutropenia was more frequent in patients in the FOLFOX arm than the LV5FU2 arm (20.0% vs. 3.1%).
Conclusion
The addition of oxaliplatin (FOLFOX) did not lead to better efficacy compared to LV5FU2 chemotherapy in an adjuvant setting in node-positive ESCC patients.

Citations

Citations to this article as recorded by  
  • Meta‐Analysis of Recurrence‐Free Survival or Disease‐Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer Trials
    Uchechukwu Love Anyaduba, Oluwatosin Qawiyy Orababa, Zion Faye, Nazia Rashid, Jason Shafrin, Gregory Reardon
    Cancer Reports.2025;[Epub]     CrossRef
  • Adjuvant chemotherapy in node‐positive patients after esophagectomy for esophageal squamous cell carcinoma
    Yeong Jeong Jeon, Jong Ho Cho, Yong Soo Choi, Young Mog Shim, Jong‐Mu Sun, Hong Kwan Kim
    Thoracic Cancer.2023; 14(6): 624.     CrossRef
  • Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis
    Jaffer A. Ajani, Lisa Leung, Prianka Singh, Murat Kurt, Inkyu Kim, Mir-Masoud Pourrahmat, Steve Kanters
    European Journal of Cancer.2022; 170: 119.     CrossRef
  • Substrate-controlled selective acylation of quinazolinones: Access to 2-benzamido-N-formylbenzamides and 3-benzoylquinazolinones
    Xianglin Yu, Peng Chen, Ling Jiang, Jun Lin, Yi Jin
    Tetrahedron Letters.2022; 103: 153988.     CrossRef
  • Catalyst-free highly regioselective hydrated ring-opening and formylation of quinazolinones
    Xianglin Yu, Zhiliang Tang, Kun He, Weina Li, Jun Lin, Yi Jin
    Organic & Biomolecular Chemistry.2022; 20(33): 6654.     CrossRef
  • Clinical Trends in Management of Locally Advanced ESCC: Real-World Evidence from a Large Single-Center Cohort Study
    Yeong Jeong Jeon, Junsang Yoo, Jong Ho Cho, Young Mog Shim
    Cancers.2022; 14(19): 4953.     CrossRef
  • Cardiotoxic effects induced by the use of antimetabolites in the chemotherapy of oncological diseases
    Alina A. Aliab'eva, Galina S. Mal
    CardioSomatics.2021; 12(3): 177.     CrossRef
  • Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients
    Hiroo Imai, Ken Saijo, Keigo Komine, Yuya Yoshida, Keiju Sasaki, Asako Suzuki, Kota Ouchi, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • Adjuvant Therapy for Esophageal Squamous Cell Carcinoma
    Jong-Mu Sun
    The Korean Journal of Thoracic and Cardiovascular Surgery.2020; 53(4): 168.     CrossRef
  • Copper-Catalyzed N-Formylation of Amines through Tandem Amination/Hydrolysis/Decarboxylation Reaction of Ethyl Bromodifluoroacetate
    Xiao-Fang Li, Xing-Guo Zhang, Fan Chen, Xiao-Hong Zhang
    The Journal of Organic Chemistry.2018; 83(20): 12815.     CrossRef
  • Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer
    Vincent T Janmaat, Ewout W Steyerberg, Ate van der Gaast, Ron HJ Mathijssen, Marco J Bruno, Maikel P Peppelenbosch, Ernst J Kuipers, Manon CW Spaander
    Cochrane Database of Systematic Reviews.2017;[Epub]     CrossRef
  • 11,460 View
  • 276 Download
  • 9 Web of Science
  • 11 Crossref
Close layer
Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Keunchil Park, Jong-Mu Sun, Young Hyeh Ko, Chung-Hwan Baek, Young-ik Son, Han Sin Jeong, Yong Chan Ahn, Min-Young Lee, Mineui Hong, Myung-Ju Ahn
Cancer Res Treat. 2016;48(2):527-536.   Published online September 15, 2015
DOI: https://doi.org/10.4143/crt.2015.249
AbstractAbstract PDFPubReaderePub
Purpose
Oropharyngeal squamous cell carcinoma (OSCC) has been recognized as an immunosuppressive disease. Various mechanisms have been proposed for immune escape, including dysregulation of immune checkpoints such as the PD-1:PD-L1 pathway. We investigated the expression of programmed cell death-ligand 1 (PD-L1) in HPV-negative and HPV-positive OSCC to determine its prevalence and prognostic relevance.
Materials and Methods
Using immunohistochemistry, 133 cases of OSCC were evaluated for expression of PD-L1. Formalin-fixed paraffin-embedded tumor samples were stained with monoclonal antibody (clone 5H1) to PD-L1. PD-L1 positivity was defined as membrane staining in ≥20% of tumor cells. Correlations between PD-L1 expression and HPV status and survival parameters were analyzed.
Results
Of the 133 patients, 68% showed PD-L1 expression, and 67% of patients were positive for p16 expression by immunohistochemistry. No significant difference in PD-L1 expression was observed between HPV(-) and HPV(+) tumors (61% vs. 71%, p=0.274). No significant difference in age, gender, smoking history, location of tumor origin, or stage was observed according to PD-L1 status. With a median follow-up period of 44 months, older age (≥65) (p=0.017) and T3-4 stage (p<0.001) were associated with poor overall survival (OS), whereas PD-L1 expression did not affect OS in univariate and multivariate analysis.
Conclusion
PD-L1 expression was observed in the majority of OSCC patients regardless of HPV status. Further large prospective studies are required to determine the role of PD-L1 expression as a prognostic or predictive biomarker, and clinical studies of immune checkpoint inhibitors in OCSS are warranted regardless of HPV status.

Citations

Citations to this article as recorded by  
  • A bibliometric analysis of immune response in oral cancer
    Rongrong Zhang, Runying Guo, Yuqi Xin, Qingkun Jiang, Jiaxuan Qiu
    Discover Oncology.2025;[Epub]     CrossRef
  • HPV frequency in oral cavity and oropharynx cancers and its association with immune checkpoint inhibitors
    Hayriye Tatlı Doğan, Mustafa Tahtacı
    Türk Tıp Dergisi.2025; 10(1): 1.     CrossRef
  • Treatment Outcomes of Squamous Cell Carcinoma of the Soft Palate and the Prognostic Significance of HPV/p16 Status
    Meng‐hua Li, Xing Zhang, Feng‐jiao Li, Xian‐lu Gao, Shi‐da Yan, Qiao‐hong Lin, Xi‐yuan Li, Jian Meng, Ying Zhang, Shi‐ting Zhang, Shu‐wei Chen, Ming Song
    Head & Neck.2025;[Epub]     CrossRef
  • Prognostic role of PD-L1 expression in head and neck squamous cell carcinoma: An institutional experience from India
    Pooja Sharma Kala, Naveen Thapliyal, Bhawna Pant, Nitin Sharma, Hari Shankar Pandey
    Pathology - Research and Practice.2024; 254: 155133.     CrossRef
  • Référentiel national de traitement des carcinomes épidermoïdes des voies aérodigestives supérieures – Principes généraux de traitement
    Béatrix Barry, Gilles Dolivet, Florian Clatot, Florence Huguet, Cyril Abdeddaim, Bertrand Baujat, Nicolas Blanchard, Gilles Calais, Xavier Carrat, Anne Chatellier, Florence Coste, Didier Cupissol, Philippe Cuvelier, Erwan De Mones Del Pujol, Sophie Deneuv
    Bulletin du Cancer.2024; 111(4): 393.     CrossRef
  • PD-L1 expression in head and neck squamous cell carcinoma and its clinical significance: A prospective observational study from a tertiary care centre
    Sindhu Kilaru, Soumya Surath Panda, Lalatendu Moharana, Debahuti Mohapatra, Satya Sundar G. Mohapatra, Adyakinkar Panda, Spoorthy Kolluri, Suma Devaraj, Ananya Kabi, Bharat Das, Ghanashyam Biswas
    Journal of Cancer Research and Therapeutics.2024; 20(1): 46.     CrossRef
  • Histologic and Genomic Analysis of Conjunctival SCC in African and American Cohorts Reveal UV Light and HPV Signatures and High Tumor Mutation Burden
    Frederico O. Gleber-Netto, Priyadharsini Nagarajan, Oded Sagiv, Curtis R. Pickering, Neil Gross, Jing Ning, Melisachew M. Yeshi, Yonas Mitku, Michael T. Tetzlaff, Bita Esmaeli
    Investigative Opthalmology & Visual Science.2024; 65(4): 24.     CrossRef
  • Considerable interlaboratory variation in PD‐L1 positivity for head and neck squamous cell carcinoma in the Netherlands— A nationwide evaluation study
    Maaike Anna Hempenius, Bregje M Koomen, Ivette A G Deckers, Sjoukje F Oosting, Stefan M Willems, Bert van der Vegt
    Histopathology.2024; 85(1): 133.     CrossRef
  • The Role of Estrogen and Estrogen Receptors in Head and Neck Tumors
    Jacqueline-Katrin Kranjčević, Josipa Čonkaš, Petar Ozretić
    Cancers.2024; 16(8): 1575.     CrossRef
  • PD-L1 Expression and Its Association With p16 in Head and Neck Squamous Cell Carcinoma in Southwestern Uganda
    Rita Nabulya, Raymond Atwine, Brian Ssenkumba, Yekosani Mitala, Jamilah Nabukenya
    Pathology and Laboratory Medicine International.2024; Volume 16: 1.     CrossRef
  • High‐risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects
    Irene Lo Cigno, Federica Calati, Carlo Girone, Marta Catozzo, Marisa Gariglio
    Journal of Medical Virology.2024;[Epub]     CrossRef
  • PD-L1 immunohistochemical expression considering HPV status in oropharyngeal squamous cell carcinoma
    Raíssa Soares dos ANJOS, Marianne de Vasconcelos CARVALHO, Rayanna Thayse Florêncio COSTA, Belmiro Cavalcanti do Egito VASCONCELOS, Sandra Lúcia Dantas MORAES, Eduardo Piza PELLIZZER
    Brazilian Oral Research.2024;[Epub]     CrossRef
  • PD-1 and PD-L1 Expression Levels as a Potential Biomarker of Chronic Rhinosinusitis and Head and Neck Cancers
    Katarzyna Malinowska, Andrzej Kowalski, Anna Merecz-Sadowska, Milena Paprocka-Zjawiona, Przemysław Sitarek, Tomasz Kowalczyk, Hanna Zielińska-Bliźniewska
    Journal of Clinical Medicine.2023; 12(5): 2033.     CrossRef
  • Immunotherapy in oral cancer: Review
    Despoina Papaioannou, Spyridoula Petsali, Alida Ndreou, Fani Akritidou, Vasileios Zisis, Dimitrios Kavvadas, Athanasios Poulopoulos, Sofia Karachrysafi, Dimitrios Andreadis
    Balkan Journal of Dental Medicine.2023; 27(3): 129.     CrossRef
  • Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma
    Amandeep Kaur, Kristine Kuchta, William Watkin, Megan Sullivan, Lin Liu, Pouya Jamshidi, Nick Campbell, Bruce Brockstein, Ajit Paintal
    Archives of Pathology & Laboratory Medicine.2023; 147(4): 442.     CrossRef
  • Expression of immune checkpoint protein in oral squamous cell carcinoma and its clinicopathological correlation: A tertiary care center cross-sectional study
    Sonal Ratnakar, Madhu Kumar, Malti K. Maurya, Sumaira Qayoom, Mala Sagar, Suresh Babu, Vijay Kumar
    Journal of Oral and Maxillofacial Pathology.2023; 27(3): 597.     CrossRef
  • Commentary on “Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma”
    Juan Francisco Peña-Cardelles, José Ernesto Moro-Rodríguez, José Luís Cebrián-Carretero, José Juan Pozo-Kreilinger
    Open Medicine.2022; 17(1): 227.     CrossRef
  • Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis
    Ramy R. Saleh, Jordan L. Scott, Nicholas Meti, Danielle Perlon, Rouhi Fazelzad, Alberto Ocana, Eitan Amir
    Molecular Diagnosis & Therapy.2022; 26(2): 153.     CrossRef
  • Immunotherapy for head and neck cancer: Present and future
    Morena Fasano, Carminia Maria Della Corte, Raimondo Di Liello, Giuseppe Viscardi, Francesca Sparano, Maria Lucia Iacovino, Fernando Paragliola, Antonio Piccolo, Stefania Napolitano, Giulia Martini, Floriana Morgillo, Salvatore Cappabianca, Fortunato Ciard
    Critical Reviews in Oncology/Hematology.2022; 174: 103679.     CrossRef
  • Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma
    Sebastian Blatt, Maximilian Krüger, Constantin Rump, Stefanie Zimmer, Keyvan Sagheb, Julian Künzel, Afsheen Raza
    PLOS ONE.2022; 17(5): e0269136.     CrossRef
  • Expression of PD-L1 is HPV/P16-independent in oral squamous cell carcinoma
    Kit Kitichotkul, Nirush Lertprasertsuke, Sompid Kintarak, Surawut Pongsiriwet, Warit Powcharoen, Anak Iamaroon
    Heliyon.2022; 8(10): e10667.     CrossRef
  • Survival Outcomes of Complete Pulmonary Metastasectomy for Head and Neck Squamous Cell Carcinomas
    Hiroaki Kuroda, Shin Koyama, Mingyon Mun, Jun Nakajima, Kazuhito Funai, Ichiro Yoshino, Yoshikane Yamauchi, Masafumi Kawamura
    Cancer Management and Research.2022; Volume 14: 3095.     CrossRef
  • Expression of PD-L1 is HPV/P16-Independent in Oral Squamous Cell Carcinoma
    Kit Kitichotkul, Nirush Lertprasertsuke, Sompid Kintarak, Surawut Pongsiriwet, Warit Powcharoen, Anak Iamaroon
    SSRN Electronic Journal .2022;[Epub]     CrossRef
  • CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma
    Songtao Zhang, Qiujie Yan, Song Wei, Xiaobo Feng, Miaomiao Xue, Lina Liu, Jili Cui, Yuanyuan Zhang
    Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2021; 132(2): 202.     CrossRef
  • PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis
    Yuan Qin, Jiaochen Luan, Xiang Zhou, Ying Li
    Bioscience Reports.2021;[Epub]     CrossRef
  • Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
    Parmida Sadat Pezeshki, Pouya Mahdavi Sharif, Nima Rezaei
    Expert Opinion on Biological Therapy.2021; 21(12): 1575.     CrossRef
  • PD-L1 TESTING AND IMMUNOTHERAPY SELECTION – EARLY LABORATORY EXPERIENCE AND ITS POTENTIAL ROLE IN HEAD AND NECK CANCER MANAGEMENT
    Bancu Bancu, Richard Cowan, Anshuman Chaturvedi
    Archive of Clinical Cases.2021; 8(1): 14.     CrossRef
  • Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus
    Huanhuan Wang, Qin Zhao, Yuyu Zhang, Qihe Zhang, Zhuangzhuang Zheng, Shiyu Liu, Zijing Liu, Lingbin Meng, Ying Xin, Xin Jiang
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis
    Emily Clarke, Jesper Grau Eriksen, Sarah Barrett
    Acta Oncologica.2021; 60(11): 1534.     CrossRef
  • Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma
    Alexander A. Strait, Rachel A. Woolaver, Spencer C. Hall, Christian D. Young, Sana D. Karam, Antonio Jimeno, Yan Lan, David Raben, Jing H. Wang, Xiao-Jing Wang
    Communications Biology.2021;[Epub]     CrossRef
  • Commentary on 'Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis' (He et al., (2020) Archives of Oral Biology, 114, 104717)
    Juan Francisco Peña-Cardelles, José Ernesto Moro-Rodríguez, José Luís Cebrián-Carretero, José Juan Pozo-Kreilinger
    Archives of Oral Biology.2021; 132: 105274.     CrossRef
  • Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
    Kimberly M. Burcher, Jeffrey W. Lantz, Elena Gavrila, Arianne Abreu, Jack T. Burcher, Andrew T. Faucheux, Amy Xie, Clayton Jackson, Alexander H. Song, Ryan T. Hughes, Thomas Lycan, Paul M. Bunch, Cristina M. Furdui, Umit Topaloglu, Ralph B. D’Agostino, We
    Cancers.2021; 13(22): 5733.     CrossRef
  • Prognostic Significance of PD-L1 Expression In Patients With Primary Oropharyngeal Squamous Cell Carcinoma: A Meta-Analysis
    Jerry Polesel, Anna Menegaldo, Giancarlo Tirelli, Vittorio Giacomarra, Roberto Guerrieri, Lorena Baboci, Mariateresa Casarotto, Valentina Lupato, Giuseppe Fanetti, Paolo Boscolo-Rizzo, Elisabetta Fratta
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Tumor Immunity and Immunotherapy for HPV-Related Cancers
    Achraf A. Shamseddine, Bharat Burman, Nancy Y. Lee, Dmitriy Zamarin, Nadeem Riaz
    Cancer Discovery.2021; 11(8): 1896.     CrossRef
  • An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives
    Daniel Lenouvel, Miguel Ángel González‐Moles, Asmae Talbaoui, Pablo Ramos‐García, Lucía González‐Ruiz, Isabel Ruiz‐Ávila, José Antonio Gil‐Montoya
    Oral Diseases.2020; 26(3): 511.     CrossRef
  • A treatise on endothelial biology and exosomes: homage to Theresa Maria Listowska Whiteside
    N. Ludwig, M. T. Lotze
    HNO.2020; 68(2): 71.     CrossRef
  • PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva
    Bastian Czogalla, Deborah Pham, Fabian Trillsch, Miriam Rottmann, Julia Gallwas, Alexander Burges, Sven Mahner, Thomas Kirchner, Udo Jeschke, Doris Mayr, Elisa Schmoeckel
    Journal of Cancer Research and Clinical Oncology.2020; 146(3): 569.     CrossRef
  • Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking
    Jacob K. Lilja-Fischer, Jesper G. Eriksen, Jeanette B. Georgsen, Thao T. Vo, Stine R. Larsen, Jonathan Cheng, Michael Busch-Sørensen, Deepti Aurora-Garg, Torben Steiniche, Jens Overgaard
    Acta Oncologica.2020; 59(6): 666.     CrossRef
  • Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment
    Lien Lippens, Mieke Van Bockstal, Emiel A. De Jaeghere, Philippe Tummers, Amin Makar, Sofie De Geyter, Koen Van de Vijver, An Hendrix, Katrien Vandecasteele, Hannelore Denys
    International Journal of Cancer.2020; 147(2): 554.     CrossRef
  • Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
    Victor C. Kok
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis
    Hui Tang, Xiang Zhou, Yu Ye, Yi Zhou, Chengyu Wu, Yan Xu
    Pathology - Research and Practice.2020; 216(1): 152768.     CrossRef
  • Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis
    Jing He, Xiao-Fang Chen, Ming-Gao Xu, Jing Zhao
    Archives of Oral Biology.2020; 114: 104717.     CrossRef
  • The role of transforming growth factor‐beta in immune suppression and chronic inflammation of squamous cell carcinomas
    Alexander A. Strait, Xiao‐Jing Wang
    Molecular Carcinogenesis.2020; 59(7): 745.     CrossRef
  • The roles of programmed death ligand 1 in virus-associated cancers
    Morvarid Golrokh Mofrad, Donya Taghizadeh Maleki, Ebrahim Faghihloo
    Infection, Genetics and Evolution.2020; 84: 104368.     CrossRef
  • Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma
    Yong-Xin Cui, Xian-Shuang Su
    Open Medicine.2020; 15(1): 292.     CrossRef
  • The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma
    Dominik Gurin, Marek Slavik, Marketa Hermanova, Iveta Selingerova, Tomas Kazda, Michal Hendrych, Tetiana Shatokhina, Marcela Vesela
    Journal of Oral Pathology & Medicine.2020; 49(9): 886.     CrossRef
  • PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma
    Nora Wuerdemann, Sibel E. Gültekin, Katharina Pütz, Claus Wittekindt, Christian U. Huebbers, Shachi J. Sharma, Hans Eckel, Anna B. Schubotz, Stefan Gattenlöhner, Reinhard Büttner, Ernst-Jan Speel, Jens P. Klussmann, Steffen Wagner, Alexander Quaas
    International Journal of Molecular Sciences.2020; 21(15): 5228.     CrossRef
  • Evaluation of p16 in Epithelial Ovarian Cancer for a 10-Year Study in Northeast China: Significance of HPV in Correlation with PD-L1 Expression


    Xinxin Yang, Qi You, Guodong Yao, Jingshu Geng, Rong Ma, Hongxue Meng
    Cancer Management and Research.2020; Volume 12: 6747.     CrossRef
  • Prevalence of high-risk human papillomavirus and its genotype distribution in head and neck squamous cell carcinomas
    Yuil Kim, Young-Hoon Joo, Min-Sik Kim, Youn Soo Lee
    Journal of Pathology and Translational Medicine.2020; 54(5): 411.     CrossRef
  • The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
    Xin-wei Qiao, Jian Jiang, Xin Pang, Mei-chang Huang, Ya-jie Tang, Xin-hua Liang, Ya-ling Tang
    Frontiers in Immunology.2020;[Epub]     CrossRef
  • Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma
    Barbara Seliger, Chiara Massa, Bo Yang, Daniel Bethmann, Matthias Kappler, Alexander Walter Eckert, Claudia Wickenhauser
    International Journal of Molecular Sciences.2020; 21(19): 7032.     CrossRef
  • PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
    D. Evrard, M. Hourseau, A. Couvelard, V. Paradis, H. Gauthier, E. Raymond, C. Halimi, B. Barry, S. Faivre
    OncoImmunology.2020;[Epub]     CrossRef
  • Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients
    Atsumu Kouketsu, Ikuro Sato, Mariko Oikawa, Yoshinaka Shimizu, Hiroki Saito, Tetsu Takahashi, Hiroyuki Kumamoto
    Journal of Cranio-Maxillofacial Surgery.2019; 47(1): 33.     CrossRef
  • The value of immunotherapy in head and neck cancer
    Paolo Manca, Luis E. Raez, Matthew Salzberg, Jorge Sanchez, Brian Hunis, Christian Rolfo
    Expert Opinion on Biological Therapy.2019; 19(1): 35.     CrossRef
  • Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route
    Iacopo Panarese, Gabriella Aquino, Andrea Ronchi, Francesco Longo, Marco Montella, Immacolata Cozzolino, Giuseppe Roccuzzo, Giuseppe Colella, Michele Caraglia, Renato Franco
    Expert Review of Anticancer Therapy.2019; 19(2): 105.     CrossRef
  • The Double-Edged Sword—How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer
    Hao-fan Wang, Sha-sha Wang, Ya-Jie Tang, Yu Chen, Min Zheng, Ya-ling Tang, Xin-hua Liang
    Frontiers in Immunology.2019;[Epub]     CrossRef
  • The protective role of carnosic acid in ischemic/reperfusion injury through regulation of autophagy under T2DM
    Min Hu, Tianyu Li, Zixiang Bo, Feixiang Xiang
    Experimental Biology and Medicine.2019; 244(7): 602.     CrossRef
  • Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva
    Fabinshy Thangarajah, Bernd Morgenstern, Caroline Pahmeyer, Lars Mortimer Schiffmann, Julian Puppe, Peter Mallmann, Stefanie Hamacher, Reinhard Buettner, Christina Alidousty, Barbara Holz, Andreas H. Scheel, Anne Maria Schultheis
    Journal of Cancer Research and Clinical Oncology.2019; 145(6): 1651.     CrossRef
  • The emergence of long-term survivors in recurrent and metastatic squamous cell head and neck cancer
    Florian Castet, Jesús Brenes, Miren Taberna, Ricard Mesía
    Current Opinion in Oncology.2019; 31(3): 160.     CrossRef
  • PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas
    Giuseppe Riva, Giancarlo Pecorari, Matteo Biolatti, Sara Pautasso, Irene Lo Cigno, Massimiliano Garzaro, Valentina Dell’Oste, Santo Landolfo
    Molecular Biology Reports.2019; 46(3): 3333.     CrossRef
  • PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma
    Priyadharsini Nagarajan, Christian El-Hadad, Stephen K. Gruschkus, Jing Ning, Courtney W. Hudgens, Oded Sagiv, Neil Gross, Michael T. Tetzlaff, Bita Esmaeli
    Investigative Opthalmology & Visual Science.2019; 60(6): 2388.     CrossRef
  • PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma
    Yui Hirata-Nozaki, Takayuki Ohkuri, Kenzo Ohara, Takumi Kumai, Marino Nagata, Shohei Harabuchi, Akemi Kosaka, Toshihiro Nagato, Kei Ishibashi, Kensuke Oikawa, Naoko Aoki, Mizuho Ohara, Yasuaki Harabuchi, Yuji Uno, Hidehiro Takei, Esteban Celis, Hiroya Kob
    Journal of Translational Medicine.2019;[Epub]     CrossRef
  • 転移・再発頭頸部がんに対する分子標的薬と免疫チェックポイント阻害薬のエビデンス

    Nippon Jibiinkoka Gakkai Kaiho.2019; 122(6): 848.     CrossRef
  • Prognostic Value of Combined Programmed Cell Death 1 Ligand and p16 Expression Predicting Responsiveness to Radiotherapy in Patients with Oropharyngeal Squamous Cell Carcinoma
    Minsu Kwon, Dae Hwan Kim, Ki Ju Cho, Youngchul Kim, Jin Pyeong Kim, Bae Kwon Jeong, Jong Sil Lee, Ji-Hyun Seo, Jung Je Park
    Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2019; 62(12): 712.     CrossRef
  • Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
    Valerie Cristina, Ruth Gabriela Herrera-Gómez, Petr Szturz, Vittoria Espeli, Marco Siano
    International Journal of Molecular Sciences.2019; 20(21): 5399.     CrossRef
  • The expression of PD-L1 in salivary gland carcinomas
    Domenic Vital, Kristian Ikenberg, Holger Moch, Matthias Rössle, Gerhard F. Huber
    Scientific Reports.2019;[Epub]     CrossRef
  • Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis
    Yi-Qun Jia, Bo Yang, Li-Ling Wen, Wen-Xin Mu, Zhi Wang, Bin Cheng
    Aging.2019; 11(2): 501.     CrossRef
  • Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance
    Nabil F. Saba, Zhuo Gerogia Chen, Missak Haigentz, Paolo Bossi, Alessandra Rinaldo, Juan P. Rodrigo, Antti A. Mäkitie, Robert P. Takes, Primoz Strojan, Jan B. Vermorken, Alfio Ferlito
    Molecular Cancer Therapeutics.2019; 18(11): 1909.     CrossRef
  • PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma
    Juan C. de Vicente, Tania Rodríguez-Santamarta, Juan P. Rodrigo, Verónica Blanco-Lorenzo, Eva Allonca, Juana M. García-Pedrero
    Cancer Epidemiology, Biomarkers & Prevention.2019; 28(3): 546.     CrossRef
  • Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma
    Theresa Scognamiglio, Yao-Tseng Chen
    Head and Neck Pathology.2018; 12(2): 221.     CrossRef
  • The Current State of Biological and Clinical Implications of Human Papillomavirus-Related Oropharyngeal Cancer
    Shao Hui Huang, Brian O'Sullivan, John Waldron
    Seminars in Radiation Oncology.2018; 28(1): 17.     CrossRef
  • Implications of the tumor immune microenvironment for staging and therapeutics
    Janis M Taube, Jérôme Galon, Lynette M Sholl, Scott J Rodig, Tricia R Cottrell, Nicolas A Giraldo, Alexander S Baras, Sanjay S Patel, Robert A Anders, David L Rimm, Ashley Cimino-Mathews
    Modern Pathology.2018; 31(2): 214.     CrossRef
  • Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
    Benjamin Solomon, Richard J. Young, Danny Rischin
    Seminars in Cancer Biology.2018; 52: 228.     CrossRef
  • Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs
    Stefano Cavalieri, Licia Rivoltini, Cristiana Bergamini, Laura D. Locati, Lisa Licitra, Paolo Bossi
    Cancer Treatment Reviews.2018; 65: 78.     CrossRef
  • Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition
    Mi Jung Kwon, Young-Soo Rho, Eun Sook Nam, Seong Jin Cho, Hye-Rim Park, Soo Kee Min, Jinwon Seo, Ji-Young Choe, Eun Soo Kim, Bumjung Park, Mineui Hong, Kyueng-Whan Min
    Human Pathology.2018; 80: 28.     CrossRef
  • The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus–Associated Head and Neck Squamous Cell Carcinoma
    Christine Kunkle, Flavia G Rosado
    Archives of Pathology & Laboratory Medicine.2018; 142(6): 719.     CrossRef
  • Genomic Landscapes of EBV-Associated Nasopharyngeal Carcinoma vs. HPV-Associated Head and Neck Cancer
    Hoi-Lam Ngan, Lan Wang, Kwok-Wai Lo, Vivian Wai Yan Lui
    Cancers.2018; 10(7): 210.     CrossRef
  • PD‐1 and PD‐L1 expression in HNSCC primary cancer and related lymph node metastasis – impact on clinical outcome
    Sven Schneider, Lorenz Kadletz, Robert Wiebringhaus, Lukas Kenner, Edgar Selzer, Thorsten Füreder, Orsolya Rajky, Anna S Berghoff, Matthias Preusser, Gregor Heiduschka
    Histopathology.2018; 73(4): 573.     CrossRef
  • The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis
    Wei-fa Yang, May C.M. Wong, Peter J. Thomson, Kar-Yan Li, Yu-xiong Su
    Oral Oncology.2018; 86: 81.     CrossRef
  • Prognostic value of PD -L1 expression in patients with primary solid tumors
    Xiao Xiang, Peng-Cheng Yu, Di Long, Xiao-Li Liao, Sen Zhang, Xue-Mei You, Jian-Hong Zhong, Le-Qun Li
    Oncotarget.2018; 9(4): 5058.     CrossRef
  • Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy
    Tatiana Lepikhova, Piia-Riitta Karhemo, Riku Louhimo, Bhagwan Yadav, Astrid Murumägi, Evgeny Kulesskiy, Mikko Kivento, Harri Sihto, Reidar Grénman, Stina M. Syrjänen, Olli Kallioniemi, Tero Aittokallio, Krister Wennerberg, Heikki Joensuu, Outi Monni
    Molecular Cancer Therapeutics.2018; 17(9): 2060.     CrossRef
  • Immune check point inhibitors for head and neck cancer
    Naomi Kiyota
    Toukeibu Gan.2018; 44(4): 336.     CrossRef
  • Immune check point inhibitors for head and neck cancer and its proper management on utilizing head and neck cancer collaborative program
    Naomi Kiyota
    Journal of Japanese Society of Oral Oncology.2018; 30(4): 144.     CrossRef
  • Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study
    Matthias Troeltzsch, Timothy Woodlock, Alix Pianka, Sven Otto, Markus Troeltzsch, Michael Ehrenfeld, Thomas Knösel
    Journal of Oral and Maxillofacial Surgery.2017; 75(5): 969.     CrossRef
  • Actualités sur l’immunothérapie en pathologie des voies aérodigestives supérieures
    Sophie Outh-Gauer, Christophe Le Tourneau, Chloé Broudin, Florian Scotte, Hélène Roussel, Stéphane Hans, Marion Mandavit, Eric Tartour, Cécile Badoual
    Annales de Pathologie.2017; 37(1): 79.     CrossRef
  • Overview of Sinonasal and Ventral Skull Base Malignancy Management
    Peter F. Svider, Michael Setzen, Soly Baredes, James K. Liu, Jean Anderson Eloy
    Otolaryngologic Clinics of North America.2017; 50(2): 205.     CrossRef
  • PD-L1 expression and CD8+ infiltration shows heterogeneity in Juvenile Recurrent Respiratory Papillomatosis
    Tingyu Liu, Max Greenberg, Carissa Wentland, Brandon Sepe, Sarah Bowe, Gillian Diercks, Tiffany Huynh, Mari Mino-Kenudson, Richard Schlegel, David Kodack, Cyril Benes, Jeffrey Engelman, Christopher Hartnick
    International Journal of Pediatric Otorhinolaryngo.2017;[Epub]     CrossRef
  • Programmed cell death ligand 1 as a biomarker in head and neck cancer
    Sara I. Pai, William C. Faquin
    Cancer Cytopathology.2017; 125(7): 529.     CrossRef
  • Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck
    Astrid De Meulenaere, Tijl Vermassen, Sandrine Aspeslagh, Wouter Huvenne, Jo Van Dorpe, Liesbeth Ferdinande, Sylvie Rottey
    Oral Oncology.2017; 70: 34.     CrossRef
  • Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years
    Linnea Haeggblom, Torbjörn Ramqvist, Massimo Tommasino, Tina Dalianis, Anders Näsman
    Papillomavirus Research.2017; 4: 1.     CrossRef
  • The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
    Panagiotis Balermpas, Franz Rödel, Mechthild Krause, Annett Linge, Fabian Lohaus, Michael Baumann, Inge Tinhofer, Volker Budach, Ali Sak, Martin Stuschke, Eleni Gkika, Anca-Ligia Grosu, Amir Abdollahi, Jürgen Debus, Stefan Stangl, Ute Ganswindt, Claus Bel
    International Journal of Cancer.2017; 141(3): 594.     CrossRef
  • Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis
    Ji Li, Ping Wang, Youliang Xu, Jung Weon Lee
    PLOS ONE.2017; 12(6): e0179536.     CrossRef
  • Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients
    Feng Yang-Chun, Cheng Zhen-Zhen, Huang Yan-Chun, Ma Xiu-Min
    Medicine.2017; 96(25): e7270.     CrossRef
  • Expressions of programmed death (PD)‐1 and PD‐1 ligand (PD‐L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status
    Wen Yang, Yan‐Ping Lu, Yi‐Zhou Yang, Jia‐Rui Kang, Yi‐Duo Jin, Hong‐Wei Wang
    Journal of Obstetrics and Gynaecology Research.2017; 43(10): 1602.     CrossRef
  • Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
    Chiun Hsu, Se-Hoon Lee, Samuel Ejadi, Caroline Even, Roger B. Cohen, Christophe Le Tourneau, Janice M. Mehnert, Alain Algazi, Emilie M.J. van Brummelen, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Aaron R. Hansen
    Journal of Clinical Oncology.2017; 35(36): 4050.     CrossRef
  • Human papillomavirus-related oropharyngeal cancer
    M. Taberna, M. Mena, M.A. Pavón, L. Alemany, M.L. Gillison, R. Mesía
    Annals of Oncology.2017; 28(10): 2386.     CrossRef
  • Circulating tumour cell PD-L1 test for head and neck cancers
    Arutha Kulasinghe, Liz Kenny, Chamindie Punyadeera
    Oral Oncology.2017; 75: 6.     CrossRef
  • Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer
    Astrid De Meulenaere, Tijl Vermassen, Sandrine Aspeslagh, Philippe Deron, Fréderic Duprez, Debby Laukens, Jo Van Dorpe, Liesbeth Ferdinande, Sylvie Rottey
    Oncotarget.2017; 8(46): 80443.     CrossRef
  • Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
    Axel Lechner, Hans Schlößer, Sacha I. Rothschild, Martin Thelen, Sabrina Reuter, Peter Zentis, Alexander Shimabukuro-Vornhagen, Sebastian Theurich, Kerstin Wennhold, Maria Garcia-Marquez, Lars Tharun, Alexander Quaas, Astrid Schauss, Jörg Isensee, Tim Huc
    Oncotarget.2017; 8(27): 44418.     CrossRef
  • Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology
    Thomas Hecking, Thore Thiesler, Cynthia Schiller, Jean-Marc Lunkenheimer, Tiyasha H. Ayub, Andrea Rohr, Mateja Condic, Mignon-Denise Keyver-Paik, Rolf Fimmers, Jutta Kirfel, Walther Kuhn, Glen Kristiansen, Kirsten Kübler
    Oncotarget.2017; 8(54): 92890.     CrossRef
  • Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data
    Gustavo Dix Junqueira Pinto, Luciano de Souza Viana, Cristovam Scapulatempo Neto, Sérgio Vicente Serrano
    Journal of Immunology Research.2016; 2016: 1.     CrossRef
  • Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
    Marlon C. Rebelatto, Anita Midha, Amita Mistry, Constantine Sabalos, Nicole Schechter, Xia Li, Xiaoping Jin, Keith E. Steele, Paul B. Robbins, John A. Blake-Haskins, Jill Walker
    Diagnostic Pathology.2016;[Epub]     CrossRef
  • Current clinical immunotherapeutic approaches for head and neck cancer
    Carolina Soto Chervin, Bruce Brockstein
    F1000Research.2016; 5: 803.     CrossRef
  • PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials
    Angela M Hong, Ricardo E Vilain, Sarah Romanes, Jean Yang, Elizabeth Smith, Deanna Jones, Richard A Scolyer, C Soon Lee, Mei Zhang, Barbara Rose
    Oncotarget.2016; 7(47): 77010.     CrossRef
  • 17,627 View
  • 347 Download
  • 111 Web of Science
  • 104 Crossref
Close layer
Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer
Jae Myoung Noh, Yong Chan Ahn, Hyebin Lee, Hongryull Pyo, BoKyong Kim, Dongryul Oh, Hyojung Park, Eonju Lee, Keunchil Park, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun
Cancer Res Treat. 2015;47(4):645-652.   Published online February 12, 2015
DOI: https://doi.org/10.4143/crt.2014.144
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to evaluate the treatment outcomes following definitive bimodality concurrent chemoradiotherapy (CCRT) in patients with inoperable N2-positive stage IIIA (N2- IIIA) non-small cell lung cancer (NSCLC). Materials and Methods From May 1997 to December 2012, 65 out of 633 patients with N2-IIIA NSCLC received bimodality therapy. The treatment modality was selected during/after neoadjuvant CCRT in 21 patients or primarily at diagnosis in 44 through a multidisciplinary consensus meeting. The median age was 65 years (range, 36 to 76 years). Sixty patients (92.3%) had clinically evident N2 disease, while 22 (33.8%) had multi-station N2 involvement. The median radiation therapy dose was 66 Gy in 33 fractions, while the dose was elevated to 72 Gy in 13 patients who had a treatment break due to delayed decision regarding resectability. The most frequent chemotherapy regimen was weekly paclitaxel or docetaxel plus cisplatin or carboplatin (54, 83.1%).
Results
During the median follow-up of 18.8 months (range, 1.6 to 173.1 months), 34 patients (52.3%) experienced disease progression, with distant metastasis being the most common first treatment failure pattern (23, 34.8%). The median and 2-year rates of progression-free survival were 18.8 months and 45.9%, respectively. The median and 2-year rates of overall survival were 28.6 months and 50.1%, respectively. Conclusion Definitive bimodality therapy in patients with N2-IIIA NSCLC demonstrated favorable outcomes, while trimodality therapy could be considered for candidates for less than pneumonectomy.

Citations

Citations to this article as recorded by  
  • Clinical N Staging Subclassification for Stage III-N2 NSCLC Patients Undergoing Trimodality Therapy: A Good Beginning Is Half the Battle
    Junghee Lee, Yun Soo Hong, Jin Lee, Genehee Lee, Danbee Kang, Jiyoun Park, Yeong Jeong Jeon, Seong Yong Park, Jong Ho Cho, Yong Soo Choi, Jhingook Kim, Young Mog Shim, Eliseo Guallar, Juhee Cho, Hong Kwan Kim
    The Annals of Thoracic Surgery.2025;[Epub]     CrossRef
  • Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer
    Kyungmi Yang, Yang-Gun Suh, Hyunju Shin, Hongryull Pyo, Sung Ho Moon, Yong Chan Ahn, Dongryul Oh, Eunah Chung, Kwanghyun Jo, Jae Myoung Noh
    Life.2022; 12(2): 292.     CrossRef
  • Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer
    Hyunju Shin, Jae Myoung Noh, Hongryull Pyo, Yong Chan Ahn, Dongryul Oh
    Radiation Oncology Journal.2021; 39(1): 24.     CrossRef
  • Experiences of patients with lung cancer receiving concurrent chemo-radiotherapy
    Choi Eunsook, Park Sunhee
    Clinical Journal of Nursing Care and Practice.2021; 5(1): 015.     CrossRef
  • Prognostic significance of tumor poliovirus receptor and CTLA4 expression in patients with surgically resected non-small-cell lung cancer
    Hui You, Yi-Zhong Zhang, Huan-Ling Lai, Dan Li, Yu-Quan Liu, Run-Ze Li, Imran Khan, Wendy Wen-Lun Hsiao, Fu-Gang Duan, Xing-Xing Fan, Xiao-Jun Yao, Ya-Bing Cao, Qi-Biao Wu, Elaine Lai-Han Leung, Mei-Fang Wang
    Journal of Cancer Research and Clinical Oncology.2020; 146(6): 1441.     CrossRef
  • Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study
    Liwen Xiong, Rong Li, Jiayuan Sun, Yuqing Lou, Weiyan Zhang, Hao Bai, Huiming Wang, Jie Shen, Bo Jing, Chunlei Shi, Hua Zhong, Aiqin Gu, Liyan Jiang, Jianxing Shi, Wentao Fang, Heng Zhao, Jie Zhang, Junyuan Wang, Junyi Ye, Baohui Han
    The Oncologist.2019; 24(2): 157.     CrossRef
  • Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer
    Junghee Lee, Hong Kwan Kim, Byung Jo Park, Jong Ho Cho, Yong Soo Choi, Jae Ill Zo, Young Mog Shim, Hongryull Pyo, Yong Chan Ahn, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jhingook Kim
    Lung Cancer.2018; 115: 89.     CrossRef
  • 14,063 View
  • 89 Download
  • 5 Web of Science
  • 7 Crossref
Close layer
Case Report
Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma
Ji Yun Lee, Sung Hee Lim, Ji Young Lee, Ji Hoon Kim, Ki Hong Choi, Keunchil Park, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn
Cancer Res Treat. 2013;45(4):343-348.   Published online December 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.4.343
AbstractAbstract PDFPubReaderePub
Tumor lysis syndrome (TLS) has rarely been observed in solid tumors. We report on a case of a patient with advanced invasive thymoma who developed tumor lysis syndrome after chemotherapy. The potential complications of TLS should be considered in treatment of extensive thymoma.

Citations

Citations to this article as recorded by  
  • Spontaneous tumour lysis syndrome as a rare presentation of thymoma with peripheral blood lymphocytosis
    Larry E Nyanti, Andy Sing Ong Tang, Adam Malik b Ismail, Lee Ping Chew, Tze Shin Leong
    Proceedings of Singapore Healthcare.2022;[Epub]     CrossRef
  • Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases
    Riyadh M Alqurashi , Husam H Tamim, Ziyad D Alsubhi, Alyazid A Alzahrani, Emad Tashkandi
    Cureus.2022;[Epub]     CrossRef
  • Spontaneous tumour lysis syndrome in cervical cancer
    Yu Kyung Kim, Ji Yeon Ham, Won-Kil Lee, Kyung Eun Song
    Journal of Obstetrics and Gynaecology.2017; 37(5): 679.     CrossRef
  • Ifosfamide/mesna/paclitaxel

    Reactions Weekly.2015; 1547(1): 151.     CrossRef
  • Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature
    Aibek E. Mirrakhimov, Alaa M. Ali, Maliha Khan, Aram Barbaryan
    Rare Tumors.2014; 6(2): 68.     CrossRef
  • 11,431 View
  • 58 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
Original Article
Predictive Value of the ERCC1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy
Jina Yun, Kyoung-Mee Kim, Seung Tae Kim, Jung-Hoon Kim, Jung A Kim, Jee Hyun Kong, Soo Hyeon Lee, Young-Woong Won, Jong-Mu Sun, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Cancer Res Treat. 2010;42(2):101-106.   Published online June 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.2.101
AbstractAbstract PDFPubReaderePub
Purpose

The aim of this study was to determine whether the ERCC1 expression is effective to predict the clinical outcomes of patients with advanced gastric cancer (AGC) and who were treated with cisplatin-based first-line chemotherapy.

Materials and Methods

A total of 89 measurable AGC patients received cisplatin and capecitabine, with or without epirubicin, as a part of a randomized phase II study. Patients were included for the current molecular analysis if they had received two or more cycles of chemotherapy, their objective tumor responses were measured and if their paraffin-embedded tumor samples were available. The ERCC1 expression was examined by performing immunohistochemical (IHC) staining, and the patients were divided into two groups (positive or negative) according to the presence of IHC staining of the tumor cell nuclei.

Results

Of the 32 eligible patients, 21 patients (66%) had tumor with a positive expression of ERCC1 and the remaining 11 patients had tumor with a negative ERCC1-expression. The ERCC1-negative patients achieved a higher response rate than that of the ERCC1-positive patients (44% vs. 28%, respectively), although the difference was not statistically significant (p=0.42). The median survival time for the all patients was 14.6 months (95% CI: 13.6 to 15.6 months). The one-year survival rate was similar for the ERCC1-negative patients (61%) and the ERCC1-positive patients (70%).

Conclusion

In the current study, the tumor ERCC1 expression by IHC staining could not predict the clinical response or survival of AGC patients who were treated with cisplatin-based first-line chemotherapy. The ERCC1 protein expression does not appear to be a useful tool for the selection of tailored chemotherapy for these patients.

Citations

Citations to this article as recorded by  
  • Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review
    Eduardo Henrique Cunha Neves Filho, Rosane Oliveira de Sant'Ana, Luiz Vianney Saldanha Cidrão Nunes, Adriana Pinheiro Bezerra Pires, Maria do Perpétuo Socorro Saldanha da Cunha
    APMIS.2017; 125(2): 79.     CrossRef
  • Predictive biomarkers for targeted and cytotoxic agents in gastric cancer for personalized medicine
    Shalong Wang, Lianwen Yuan
    BioScience Trends.2016; 10(3): 171.     CrossRef
  • Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy
    Zheng-mao Lu, Tian-hang Luo, Ming-ming Nie, Guo-en Fang, Li-ye Ma, Xu-chao Xue, Guo Wei, Chong-we Ke, Jian-wei Bi
    Tumor Biology.2014; 35(4): 2941.     CrossRef
  • The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis
    Kong-Kong Wei, Lei Jiang, Yao-Yao Wei, Yu-Feng Wang, Xuan-Kun Qian, Qiang Dai, Quan-Lin Guan
    Tumor Biology.2014; 35(9): 8721.     CrossRef
  • Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis
    Anqi Yao, You Wang, Xiaohong Peng, Rong Ye, Qiaoli Wang, Yuexiao Qi, Fuxiang Zhou
    Journal of Cancer Research and Clinical Oncology.2014; 140(12): 2107.     CrossRef
  • Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term
    Liqi Chen, Guoli Li, Jieshou Li, Chaogang Fan, Jian Xu, Bo Wu, Kun Liu, Caihua Zhang
    Cancer Chemotherapy and Pharmacology.2013; 71(4): 921.     CrossRef
  • ERCC1 C19007T polymorphism and the risk and invasiveness of cervical cancer in Korean women
    Seung‐Su HAN, Jae Weon KIM, Sang Hoon LEE, Dong Ho KIM, Noh‐Hyun PARK, Yong‐Sang SONG, Soon‐Beom KANG
    Asia-Pacific Journal of Clinical Oncology.2012;[Epub]     CrossRef
  • Gastric Cancer
    Joshua D. Lawson, Jason K. Sicklick, Paul T. Fanta
    Current Problems in Cancer.2011; 35(3): 97.     CrossRef
  • 10,309 View
  • 42 Download
  • 8 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP